Grants paid by Alzheimer's Disease Research Foundation
EIN 52-2396428 · Wellesley Hls, MA · Form 990, Schedule I · NTEE H83
Alzheimer's Disease Research Foundation of Wellesley Hls, MA (EIN 52-2396428) reported 707 grants paid totaling $158,535,079 to 88 recipients in tax years 2018–2025, on Form 990, Schedule I. Derived from IRS e-file data, dataset version 2026.09.0, built 2026-09-03.
Grants paid
$158,535,079
707 grants
Recipients
88
distinct organizations
Tax years
2018–2025
8 filings in the corpus
By tax year
| Tax year | Grants paid | Amount paid | Approved for future |
|---|---|---|---|
| 2018 | 67 | $15,720,439 | — |
| 2019 | 67 | $15,431,965 | — |
| 2020 | 47 | $11,742,907 | — |
| 2021 | 76 | $15,183,443 | — |
| 2022 | 85 | $19,108,307 | — |
| 2023 | 98 | $23,118,277 | — |
| 2024 | 106 | $24,417,387 | — |
| 2025 | 161 | $33,812,354 | — |
Top recipients
The 88 recipients receiving the most from Alzheimer's Disease Research Foundation, by grants paid, out of 88 distinct recipients.
| Recipient | Match | Location | Grants | Total paid | Latest year |
|---|---|---|---|---|---|
| Massachusetts General Hospital 04-1564655 | A | Charlestown, MA | 109 | $35,278,456 | 2025 |
| Washington University 43-0653611 | A | St Louis, MO | 70 | $14,835,158 | 2025 |
| Brigham and Women's 04-2312909 | A | Boston, MA | 31 | $7,963,071 | 2025 |
| University of California San Diego 95-2872494 | A | La Jolla, CA | 26 | $5,643,598 | 2025 |
| Weill Cornell 13-6094042 | A | New York, NY | 26 | $5,580,050 | 2025 |
| Mount Sinai 13-6171197 | A | New York, NY | 27 | $4,803,134 | 2025 |
| Harvard Medical School 04-2103580 | A | Boston, MA | 23 | $4,366,849 | 2025 |
| Mayo Jacksonville 59-3337028 | A | Jacksonville, FL | 21 | $4,180,000 | 2025 |
| University of Southern California 95-1642394 | A | Los Angeles, CA | 18 | $4,148,975 | 2025 |
| The Regents of the University of Califormia San Francisco 94-3067788 | A | San Francisco, CA | 18 | $3,594,546 | 2025 |
| Northwestern 36-2167817 | A | Chicago, IL | 16 | $3,439,809 | 2025 |
| Massachusetts General Hospital 04-2697983 | A | Boston, MA | 15 | $3,217,252 | 2025 |
| University of Virginia 54-6001796 | A | Charlottesville, VA | 16 | $3,113,512 | 2025 |
| Boston Children's Hospital 04-2774441 | A | Boston, MA | 14 | $3,002,651 | 2025 |
| New York University 13-5562308 | A | New York, NY | 14 | $2,892,882 | 2025 |
| Broad Institute 26-3428781 | A | Cambridge, MA | 8 | $2,826,257 | 2025 |
| University of California Irvine 95-2226406 | A | Irvine, CA | 9 | $2,368,725 | 2025 |
| Rockefeller 13-1624158 | A | New York, NY | 9 | $2,007,500 | 2022 |
| Boston University 04-2103547 | A | Boston, MA | 11 | $1,962,707 | 2023 |
| University of Texas Southwestern Medical Center 75-2556007 | A | Dallas, TX | 8 | $1,879,000 | 2023 |
| Salk 95-2160097 | A | La Jolla, CA | 12 | $1,869,250 | 2025 |
| Yale 06-0646973 | A | New Haven, CT | 10 | $1,757,993 | 2024 |
| University of Michigan 38-6006309 | A | Ann Arbor, MI | 8 | $1,756,370 | 2025 |
| Duke 56-2247203 | A | Durham, NC | 9 | $1,699,093 | 2025 |
| Houston Methodist 76-0094743 | A | Houston, TX | 9 | $1,684,866 | 2025 |
| Stanford 94-1156365 | A | Stanford, CA | 8 | $1,630,374 | 2025 |
| Massachusetts Institute of Technology 04-2103594 | A | Cambridge, MA | 7 | $1,582,229 | 2025 |
| Beth Israel Deaconess Medical Center 04-2103881 | A | Boston, MA | 8 | $1,573,666 | 2025 |
| University of Chicago 36-2177139 | A | Chicago, IL | 7 | $1,524,625 | 2024 |
| Mayo Clinic 41-6011702 | A | Rochester, MN | 8 | $1,486,250 | 2025 |
| Columbia University 13-5598093 | A | New York, NY | 7 | $1,239,905 | 2025 |
| Carnegie Mellon 25-0969449 | A | Pittsburgh, PA | 6 | $1,199,534 | 2025 |
| University of Texas Health Science Center at San Antonio 74-1586031 | A | San Antonio, TX | 6 | $1,187,254 | 2025 |
| Mskcc 13-1924236 | A | New York, NY | 6 | $1,156,250 | 2025 |
| Washington University St Louis | U | St Louis, MO | 6 | $1,146,731 | 2018 |
| Whitehead 06-1043412 | A | Cambridge, MA | 5 | $1,138,250 | 2022 |
| Gladstone Institutes 23-7203666 | A | San Francisco, CA | 5 | $1,120,938 | 2025 |
| Amylyx 46-4600503 | A | Cambridge, MA | 3 | $928,234 | 2021 |
| The University of California San Diego | U | La Jolla, CA | 3 | $833,750 | 2018 |
| Tufts 04-2103634 | A | Boston, MA | 5 | $796,875 | 2025 |
| Johns Hopkins University 52-0595110 | A | Baltimore, MD | 4 | $747,447 | 2025 |
| National Institute of Neurological Disorders & Stroke 52-0858115 | A | Bethesda, MD | 3 | $655,673 | 2025 |
| Baylor College of Medicine 74-1613878 | A | Houston, TX | 4 | $611,557 | 2025 |
| University of Rochester 16-0743209 | A | Rochester, NY | 2 | $575,000 | 2025 |
| University of Pennsylvania 23-1352685 | A | Philadelphia, PA | 2 | $570,630 | 2025 |
| Wake Forest 22-3849199 | A | Winstonsalem, NC | 3 | $546,250 | 2024 |
| University of Texas Southwestern Medical Center 75-6002868 | A | Dallas, TX | 2 | $517,276 | 2025 |
| University of Virginia | U | Charlottesville, VA | 2 | $460,000 | 2018 |
| University of Connecticut 06-0772160 | A | Farmington, CT | 2 | $460,000 | 2023 |
| Duke University School of Medicine 56-0532129 | A | Durham, NC | 2 | $425,428 | 2023 |
| University of California San Francisco 94-6036493 | A | San Francisco, CA | 2 | $402,500 | 2022 |
| University of Rhode Island 22-3011455 | A | Kingston, RI | 2 | $402,500 | 2024 |
| Emory University 58-0566256 | A | Atlanta, GA | 2 | $402,500 | 2025 |
| University of Washington 91-6001537 | A | Seattle, WA | 2 | $401,293 | 2025 |
| Univeristy of California Los Angeles 95-6006143 | A | Los Angeles, CA | 2 | $392,713 | 2025 |
| Indiana University 35-6001673 | A | Bloomington, IN | 2 | $381,050 | 2024 |
| Johns Hopkins 99-9999999 | A | Baltimore, MD | 2 | $372,127 | 2022 |
| Burke Neurological Institute 13-3434924 | A | White Plains, NY | 2 | $346,014 | 2025 |
| Palo Alto Veterans Institute for Research 77-0207331 | A | Palo Alto, CA | 2 | $345,000 | 2019 |
| Unc-Chapel Hill 56-6001393 | A | Chapel Hill, NC | 2 | $345,000 | 2022 |
| Weill Medical College of Cornell University | U | New York, NY | 2 | $343,361 | 2018 |
| The Mclean Hospital Corporation 04-2697981 | A | Belmont, MA | 1 | $327,501 | 2025 |
| University of Kentucky 61-6033693 | A | Lexington, KY | 2 | $278,277 | 2025 |
| University of Alabama at Birmingham 63-6005396 | A | Birmingham, AL | 1 | $271,375 | 2025 |
| New York University School of Medicine 37-1592643 | C | New York, NY | 1 | $250,000 | 2018 |
| University of Michigan | U | Ann Arbor, MI | 1 | $241,738 | 2018 |
| University of South Florida 59-3102112 | A | Tampa, FL | 1 | $201,250 | 2025 |
| Dana-Farber Cancer Institute Inc 04-2263040 | A | Boston, MA | 1 | $201,250 | 2024 |
| Augusta University Research Institute Inc 58-1418202 | A | Augusta, GA | 1 | $201,250 | 2025 |
| University of Massachusetts Chan Medical School 04-3167352 | A | Worcester, MA | 1 | $200,568 | 2025 |
| University of North Carolina at Charlotte 58-2040339 | B | Charlotte, NC | 1 | $200,000 | 2018 |
| Albert Einstein College of Medicine 83-0621846 | A | Bronx, NY | 2 | $200,000 | 2022 |
| St Jude Children's Research Hospital 62-0646012 | A | Memphis, TN | 2 | $184,000 | 2025 |
| Seattle Neurosound Solutions 88-4199640 | A | Seattle, WA | 1 | $175,000 | 2025 |
| Sanford Burnham Prebys Medical Discovery Institute 51-0197108 | A | La Jolla, CA | 1 | $172,500 | 2019 |
| University of Connecticut Health Center | U | Farmington, CT | 1 | $172,500 | 2018 |
| Unversity of Kentucky 61-6001218 | A | Lexington, KY | 1 | $172,500 | 2021 |
| University of Connecticut Health Center 23-7187838 | A | Farmington, CT | 1 | $172,500 | 2019 |
| State of Maryland -University of Maryland Baltimore | U | Baltimore, MD | 1 | $171,037 | 2025 |
| Stony Brook 16-1514621 | A | Stony Brook, NY | 2 | $132,217 | 2022 |
| University of Pittsburgh 25-0965591 | A | Pittsburgh, PA | 1 | $100,625 | 2025 |
| Massachusetts Institute of Techonology 04-2103597 | A | Cambridge, MA | 1 | $100,000 | 2021 |
| New York Genome Center 80-0631734 | A | New York, NY | 1 | $86,250 | 2025 |
| Maryland Medical Legal Foundation 52-0786068 | A | Baltimore, MD | 1 | $57,500 | 2025 |
| University of Rhode Island 36-4644408 | A | Kingston, RI | 1 | $56,404 | 2019 |
| University of Miami 59-0624458 | A | Atlanta, GA | 2 | $49,178 | 2025 |
| The Brain Donor Project 81-2333601 | A | Naples, FL | 1 | $35,050 | 2021 |
| Medical College of Wisconsin 39-0806261 | A | Milwaukee, WI | 1 | $4,721 | 2024 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Every grant
All 707 grant rows this organization reported, most recent first.
| Tax year | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|
| 2025 | Massachusetts General Hospital Boston, MA | A | $1,955,000 | paid | THE CUREALZ ALZHEIMER'S GENOME PROJECT | 202641319349301469 |
| 2025 | Brigham and Women's Hospital Boston, MA | A | $575,000 | paid | APOE4 ACCELERATES CD8 EXHAUSTION VIA GLUCOCORTICOID SIGNALING IN ALZHEIMER'S FEMALE CARRIERS | 202641319349301469 |
| 2025 | Brigham and Women's Hospital Boston, MA | A | $431,250 | paid | A NEW MODEL OF MICROGLIA GENETIC PERTURBATION IN VIVO TO SCREEN ALL RISK FACTORS ASSOCIATED WITH ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | University of Michigan Ann Arbor, MI | A | $402,500 | paid | NON-INVASIVE MODULATION OF MICROGLIA GENE EXPRESSION USING PERIPHERALLY ADMINISTERED ANTIBODY CONJUGATES | 202641319349301469 |
| 2025 | Weill Medical College of Cornell University New York, NY | A | $402,500 | paid | SEX-BIASED TLR7 SIGNALING IN DEMYELINATION AND ITS INHIBITION BY SMALL MOLECULES | 202641319349301469 |
| 2025 | University of California Irvine Irvine, CA | A | $402,492 | paid | PROTEOMIC SIGNATURES OF CEREBROVASCULAR NEUROPATHOLOGY IN DOWN SYNDROME WITH ALZHEIMER DISEASE | 202641319349301469 |
| 2025 | University of Michigan Ann Arbor, MI | A | $398,521 | paid | UTILIZING HETEROGENEOUS MOUSE MODELS TO DISCOVER MECHANISMS UNDERLYING CALORIC RESTRICTION (CR) ON COGNITIVE OUTCOMES | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $345,000 | paid | BAC: IDENTIFYING AGE-RELATED PROTEOMIC CHANGES THAT PREDICT FUTURE ONSET OF AMYLOID-BETA AGGREGATION IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $345,000 | paid | APOE CONSORTIUM: INVESTIGATING POTENTIAL CELL AUTONOMOUS NEUROPROTECTION OF APOE PROTECTIVE VARIANTS | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $345,000 | paid | BEE: MENINGEAL MAST CELL CONTROL OF CSF DYNAMICS IN HOMEOSTASIS AND ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Boston Children's Hospital Boston, MA | A | $344,528 | paid | NIC: EFFECTS OF PERIPHERAL INFLAMMATION ON MYELOID CELL FUNCTION IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | The Mclean Hospital Corporation Belmont, MA | A | $327,501 | paid | EXPANDING POSTMORTEM BRAIN RESOURCES FOR ALZHEIMER'S DISEASE IN DIVERSE POPULATIONS | 202641319349301469 |
| 2025 | Duke University School of Medicine Durham, NC | A | $320,033 | paid | UTILITY OF BLOOD BASED MARKERS FOR PREDICTING ARIA AND ITS COURSE IN MCI AND AD SUBJECTS UNDERGOING ROUTINE CLINICAL TREATMENT WITH AMYLOID-DIRECTED ANTIBODIES | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $300,000 | paid | UNDERSTANDING HUMAN BRAIN RESILIENCE TO ALZHEIMER'S PATHOLOGY | 202641319349301469 |
| 2025 | National Institute of Neurological Disorders & Stroke Bethesda, MD | A | $287,673 | paid | BEE: HIGH-RESOLUTION MRI OF THE BRAIN BORDERS | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $287,500 | paid | BEE: HUMAN 3D NEURO-VASCULAR INTERACTION AND MENINGEAL LYMPHATICS MODELS WITH APPLICATION TO ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | New York University School of Medicine New York, NY | A | $287,500 | paid | NIC: ASTROCYTE INFLAMMATORY CONTRIBUTIONS TO AD | 202641319349301469 |
| 2025 | Stanford University Redwood City, CA | A | $287,500 | paid | BAC: CHOROID PLEXUS AGING AND ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Regents of the University of California San Diego La Jolla, CA | A | $287,500 | paid | BEE: HOW DOES VASCULAR FATTY ACID METABOLISM REGULATE THE PATHOPHYSIOLOGY OF ALZHEIMER'S DISEASE? | 202641319349301469 |
| 2025 | University of Rochester Rochester, NY | A | $287,500 | paid | BEE: DOES SLYM FAILURE COMPROMISE GLYMPHATIC CLEARANCE IN ALZHEIMER'S DISEASE? | 202641319349301469 |
| 2025 | Regents of the University of California San Diego La Jolla, CA | A | $287,500 | paid | NIC: MECHANISMS MEDIATING MICROGLIA SENSING OF PERIPHERAL INFLAMMATION | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $287,500 | paid | BAC: BRAIN REGION AND CELL-TYPE SPECIFIC AGING FROM ACCELERATED TO RESILIENT TRAJECTORIES | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $287,499 | paid | BAC: ESTABLISHING ISOGENIC MODELS OF HUMAN NEURON AGING AND PATHWAYS RELEVANT FOR ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | University of California Irvine Irvine, CA | A | $287,490 | paid | NIC: EXAMINING THE IMPACT OF PERIPHERALLY DERIVED HUMAN MACROPHAGES IN AD PATHOGENESIS | 202641319349301469 |
| 2025 | Massachusetts Institute of Technology Cambridge, MA | A | $287,477 | paid | BAC: INVESTIGATING LIPIDOMIC PERTURBATIONS IN THE CSF WITH AGE AND ALZHEIMER'S DISEASE PROGRESSION: TOWARD MECHANISTIC INSIGHTS AND ACCESSIBLE LIPID BIOMARKERS | 202641319349301469 |
| 2025 | University of California Davis Davis, CA | A | $286,466 | paid | NIC: IMPACT OF AD POLYGENIC RISK SCORE ON MICROGLIAL RESPONSE TO PERIPHERAL INFLAMMATION | 202641319349301469 |
| 2025 | University of Pennsylvania Philadelphia, PA | A | $284,678 | paid | APOE CONSORTIUM: CELL AUTONOMOUS ROLES OF PROTECTIVE APOE VARIANTS IN MICROGLIA RESPONDING TO AMYLOID PATHOLOGY | 202641319349301469 |
| 2025 | University of Alabama at Birmingham Birmingham, AL | A | $271,375 | paid | EXPANDING DEEP SOUTH INCLUSION IN THE UAB ADRC NEUROPATHOLOGY CORE BRAIN BANK | 202641319349301469 |
| 2025 | Boston Children's Hospital Boston, MA | A | $264,500 | paid | BEE: NEUROINFLAMMATION AT THE CHOROID PLEXUS IN ALZHEIMER'S DISEASE (SUPPLEMENT) | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $258,750 | paid | EXPLORING NOVEL DRUG CANDIDATES FOR ALZHEIMER'S DISEASE THROUGH INTEGRATIVE PATHWAY ANALYSIS AND VALIDATION IN 3D CELLULAR MODELS (CFSF SUPPLEMENT) | 202641319349301469 |
| 2025 | Weill Medical College of Cornell University New York, NY | A | $258,750 | paid | A THREE-DIMENSIONAL TISSUE MODEL LINKING TAU TANGLES, AB AND MICROGLIAL CD33- ISOFORM STATE TO GENE- AND ISOFORM-EXPRESSION DYSREGULATION (CFSF SUPPLEMENT) | 202641319349301469 |
| 2025 | University of Virginia Charlottesville, VA | A | $258,750 | paid | THE ROLE OF PLANAR CELL POLARITY PROTEINS IN TAU OLIGOMER-INDUCED SYNAPSE DEGENERATION (CFSF SUPPLEMENT) | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $258,750 | paid | ALZHEIMER'S DISEASE TAU CONSORTIUM: TOXIC CONSEQUENCES OF EARLY TAU SEEDING (CFSF SUPPLEMENT) | 202641319349301469 |
| 2025 | Gladstone Institutes San Francisco, CA | A | $258,615 | paid | DECODING PROTEIN TRANSPORT ACROSS THE BLOOD-BRAIN BARRIER TO ENABLE NEW ALZHEIMER'S THERAPIES (CFSF SUPPLEMENT) | 202641319349301469 |
| 2025 | Gladstone Institutes San Francisco, CA | A | $258,573 | paid | DEVELOPING CELL-TYPE-SPECIFIC ENHANCER-AAV VECTORS TO CHARACTERIZE AND RESTORE AB- AND TAU-DEPENDENT CIRCUIT AND COGNITIVE DEFICITS IN HUMANIZED ALZHEIMER'S MOUSE MODELS (CFSF SUPPLEMENT) | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $252,076 | paid | MENOPAUSE AND RELATED MIDLIFE RISK FACTORS AND THEIR IMPACT ON PATHOLOGY AND COGNITION - THE WHIMSYAD STUDY | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $230,000 | paid | ADAM10 CLEAVAGE OF APP: PHYSIOLOGICAL FUNCTION IN BRAIN AND THERAPEUTIC POTENTIAL FOR ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Regents of the University of California San Diego La Jolla, CA | A | $230,000 | paid | APP GENE DOSE-MEDIATED DYSREGULATION OF THE ENDOLYSOSOMAL NETWORK ACTS COMPROMISE SYNAPTIC STRUCTURE AND FUNCTION LEADING TO ALZHEIMER DISEASE IN DOWN SYNDROME | 202641319349301469 |
| 2025 | President and Fellows of Harvard College Cambridge, MA | A | $230,000 | paid | MOVING THE CURE ALZHEIMER GENOME PROJECT BEYOND SIMPLE ASSOCIATIONS: INTEGRATING FUNCTIONAL INFORMATION, FINE-MAPPING AND CAUSAL INFERENCE APPROACHES INTO THE FAMILY-BASED ANALYSIS OF THE CURE ALZHEIMER WHOLE-GENOME SEQUENCING (WGS) FAMILY STUDY | 202641319349301469 |
| 2025 | University of California Irvine Irvine, CA | A | $230,000 | paid | ENGINEERED CAR-MACROPHAGES TO CLEAR TAU | 202641319349301469 |
| 2025 | Icahn School of Medicine at Mount Sinai New York, NY | A | $230,000 | paid | INVESTIGATING THE PATHOGENETIC ROLE OF MICROGLIAL MEF2C IN ALZHEIMER'S DISEASE ACROSS THE LIFESPAN: DEVELOPMENTAL PRIMING VS. ADULT RESPONSE TO INJURY | 202641319349301469 |
| 2025 | The Broad Institute Inc Cambridge, MA | A | $230,000 | paid | INVESTIGATING ALZHEIMER'S DISEASE-ASSOCIATED MEMBRANE BIOLOGY IN MICROGLIA AND NEURONS | 202641319349301469 |
| 2025 | Mayo Clinic Jacksonville Jacksonville, FL | A | $230,000 | paid | UNRAVELING MIXED PATHOLOGY AND ITS IMPACT ON THE PROTEOME IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | University of Texas Southwestern Medical Center Dallas, TX | A | $230,000 | paid | ENGINEERED CAR-MACROPHAGES TO CLEAR TAU | 202641319349301469 |
| 2025 | Brigham and Women's Hospital Boston, MA | A | $228,900 | paid | DO CLASSICAL COMPLEMENT ACTIVATION AND THE ROUTE OF ADMINISTRATION OF ANTI-AMYLOID ANTIBODIES CONTRIBUTE TO VASCULAR SIDE EFFECTS KNOWN AS ARIA? | 202641319349301469 |
| 2025 | New York University School of Medicine New York, NY | A | $210,962 | paid | MECHANISMS OF ASTROCYTE-DERIVED LIPID TOXICITY IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Duke University School of Medicine Durham, NC | A | $204,656 | paid | CONTRIBUTIONS OF IL34 SIGNALING TO MICROGLIAL FUNCTION AND ALZHEIMER'S PATHOLOGY IN MICE | 202641319349301469 |
| 2025 | University of Michigan Ann Arbor, MI | A | $201,251 | paid | MORPHOLOGICAL, ELECTROPHYSIOLOGICAL, AND TRANSCRIPTIONAL CHARACTERIZATION OF SINGLE NEURONS FROM RESILIENT AND SUSCEPTIBLE MODELS OF HUMAN AD | 202641319349301469 |
| 2025 | University of Virginia Charlottesville, VA | A | $201,250 | paid | ELUCIDATING THE ROLE OF EMERGING GENOMIC STRESS SENSORS IN AD | 202641319349301469 |
| 2025 | Mayo Clinic Jacksonville Jacksonville, FL | A | $201,250 | paid | EVALUATING THE CONTRIBUTION OF TDP-43 DYSFUNCTION AND CRYPTIC MIS-SPLICING TO AD PATHOGENESIS | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | EXPLORING NOVEL DRUG CANDIDATES FOR ALZHEIMER'S DISEASE THROUGH INTEGRATIVE PATHWAY ANALYSIS AND VALIDATION IN 3D CELLULAR MODELS | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $201,250 | paid | DECIPHERING AND RESTORING COMPUTATIONAL SET-POINTS IN ALZHEIMER'S DISEASE THROUGH SLEEP-ENHANCED NETWORK HOMEOSTASIS | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $201,250 | paid | ANTIVIRAL CYTOKINE SIGNALING PROMOTES NEURODEGENERATION IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Gladstone Institutes San Francisco, CA | A | $201,250 | paid | DEVELOPING CELL-TYPE-SPECIFIC ENHANCER-AAV VECTORS TO CHARACTERIZE AND RESTORE AB- AND TAU-DEPENDENT CIRCUIT AND COGNITIVE DEFICITS IN HUMANIZED ALZHEIMER'S MOUSE MODEL | 202641319349301469 |
| 2025 | University of Texas Health Science Center at San Antonio San Antonio, TX | A | $201,250 | paid | HOW DO MICROGLIA CONTRIBUTE TO THE SPREAD OF TAU PATHOLOGY IN ALZHEIMER'S DISEASE? | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | INTERNEURON THERAPY FOR ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $201,250 | paid | DEVELOPMENT OF SMALL MOLECULE INHIBITORS OF CHOLESTEROL 25-HYDROXYLASE | 202641319349301469 |
| 2025 | New York University School of Medicine New York, NY | A | $201,250 | paid | VIRAL INFECTIONS AND ALZHEIMER'S DISEASE RISK IN WOMEN | 202641319349301469 |
| 2025 | Weill Medical College of Cornell University New York, NY | A | $201,250 | paid | A THREE-DIMENSIONAL TISSUE MODEL LINKING TAU TANGLES, AB AND MICROGLIAL CD33- ISOFORM STATE TO GENE- AND ISOFORM-EXPRESSION DYSREGULATION | 202641319349301469 |
| 2025 | The Regents of the University of California San Francisco San Francisco, CA | A | $201,250 | paid | PROBING THE MOLECULAR UNDERPINNINGS OF HOW G PROTEIN-COUPLED RECEPTOR ADGRG1 MEDIATES PROTECTIVE RESPONSES TO ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | TAU AND B-AMYLOID ARE INNATE IMMUNE ANTIMICROBIAL PEPTIDES IN THE BRAIN | 202641319349301469 |
| 2025 | Northwestern University Chicago, IL | A | $201,250 | paid | ROLE OF TAU IN PRESYNAPTIC DYSFUNCTION DURING THE CELLULAR PHASE OF ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Mayo Clinic Jacksonville Jacksonville, FL | A | $201,250 | paid | LINKING SLEEP DYSFUNCTION TO TAU-RELATED DEGENERATION ACROSS AD VARIANTS | 202641319349301469 |
| 2025 | University of Virginia Charlottesville, VA | A | $201,250 | paid | IMPACT OF DNA DAMAGE-MEDIATED STING ACTIVATION ON MYELIN FUNCTION IN AN ALZHEIMER'S DISEASE ANIMAL MODEL | 202641319349301469 |
| 2025 | Johns Hopkins University Baltimore, MD | A | $201,250 | paid | A TEMPORALLY ALIGNED MULTIMODAL FRAMEWORK FOR INDIVIDUALIZED ALZHEIMER'S DISEASE RISK ASSESSMENT AND DEEP LEARNING-DRIVEN PROGNOSIS | 202641319349301469 |
| 2025 | Mayo Clinic Jacksonville Jacksonville, FL | A | $201,250 | paid | ELUCIDATING THE PROTECTIVE EFFECTS OF APOE2 IN THE PRESENCE OF APOE 4 GENE ALLELE IN ANIMAL MODELS | 202641319349301469 |
| 2025 | Mayo Clinic Jacksonville Jacksonville, FL | A | $201,250 | paid | THE MULTI-OMIC ROADMAP TO NEURONAL SENESCENCE IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Icahn School of Medicine at Mount Sinai New York, NY | A | $201,250 | paid | INVESTIGATING THE ASSOCIATION BETWEEN CLONAL HEMATOPOIESIS AND ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | ENGINEERING A HUMAN REGION-SPECIFIC SYSTEM TO PROBE APOE-LINKED CELLULAR VULNERABILITY AND RESILIENCE IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | CIRCUIT DYNAMICS IN APOE4 MICE | 202641319349301469 |
| 2025 | The Salk Institute for Biological Studies La Jolla, CA | A | $201,250 | paid | THE ROLE OF ASTROCYTE-SECRETED IGFBP2 IN THE PROGRESSION OF ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Mayo Clinic Rochester Rochester, MN | A | $201,250 | paid | BRIDGING THE GAP: SEX-SPECIFIC DRIVERS OF SENESCENCE UNDERLYING NEURODEGENERATION | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | CENTENARIAN MICROGLIA REVEAL A NEPRILYSIN-DEPENDENT MECHANISM OF RESILIENCE IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | RIN3 AND BIN1 INTERACTION CONNECTS ENDOSOMAL PATHOLOGY WITH AMYLOID PATHOLOGY | 202641319349301469 |
| 2025 | Regents of the University of California San Diego La Jolla, CA | A | $201,250 | paid | SON-DEPENDENT NUCLEAR SPECKLE REJUVENATION: A NOVEL PROTEOSTASIS-BASED THERAPEUTIC STRATEGY FOR ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Memorial Sloan Kettering Cancer Center New York, NY | A | $201,250 | paid | DEVELOPMENT AND MECHANISM OF AUTOPHAGY ACTIVATORS FOR TREATMENT OF ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Augusta University Research Institute Inc Augusta, GA | A | $201,250 | paid | THE IMPACT OF SOLUBLE DIETARY FIBER ON TAU-MEDIATED NEURODEGENERATION IN A MOUSE MODEL OF TAUOPATHY | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $201,250 | paid | SLEEP REINFORCES HOMEOSTATIC SET-POINTS IN NEURAL ACTIVITY AND MITIGATES NEURODEGENERATIVE DISEASE | 202641319349301469 |
| 2025 | University of Virginia Charlottesville, VA | A | $201,250 | paid | MICROGLIAL MITOCHONDRIAL DYSFUNCTION AND TAU TOXICITY IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | DEVELOPMENT OF A FLAP-TARGETED NEUROIMMUNE PET TRACER FOR IMAGING MICROGLIA IN AD | 202641319349301469 |
| 2025 | New York University School of Medicine New York, NY | A | $201,250 | paid | MIDLIFE AUTOANTIBODY PROFILES AND THE RISK OF LATE-ONSET ALZHEIMER'S DISEASE IN WOMEN | 202641319349301469 |
| 2025 | Gladstone Institutes San Francisco, CA | A | $201,250 | paid | DECODING PROTEIN TRANSPORT ACROSS THE BLOOD-BRAIN BARRIER TO ENABLE NEW ALZHEIMER'S THERAPIES | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | IDENTIFYING SEX-AWARE X-CHROMOSOME TARGETS FOR PRECLINICAL ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Carnegie Mellon University Pittsburgh, PA | A | $201,250 | paid | INTERPRETING ALZHEIMER'S DISEASE-ASSOCIATED GENETIC VARIATION AT ENHANCER REGIONS | 202641319349301469 |
| 2025 | The Regents of the University of California San Francisco San Francisco, CA | A | $201,250 | paid | ROLE OF PLATELET-DERIVED FACTORS IN AMELIORATING ALZHEIMER'S DISEASE PATHOLOGY | 202641319349301469 |
| 2025 | Columbia University New York, NY | A | $201,250 | paid | NONCODING TRANSLATION FEEDBACK LOOP IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Icahn School of Medicine at Mount Sinai New York, NY | A | $201,250 | paid | ROLE OF PSYCHOSOCIAL STRESS IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | University of Texas Health Science Center at San Antonio San Antonio, TX | A | $201,250 | paid | DIGITAL NEUROPATHOLOGY INFRASTRUCTURE FOR PRECISION MEDICINE IN SOUTH TEXAS HISPANIC AD/ADRD POPULATIONS | 202641319349301469 |
| 2025 | Beth Israel Deaconess Medical Center Boston, MA | A | $201,250 | paid | INTEGRATING SINGLE-CELL GENOMICS FOR PATHWAYS TO PROTECTION AND RESILIENCE AGAINST ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Brigham and Women's Hospital Boston, MA | A | $201,250 | paid | VIRAL INFECTIONS AND ALZHEIMER'S DISEASE RISK IN WOMEN | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $201,250 | paid | TARGETING REACTIVE ASTROCYTES AMPK SIGNALING TO SUPPRESS INFLAMMATION IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | President and Fellows of Harvard College Cambridge, MA | A | $201,250 | paid | MENINGEAL TREGS IN INDIVIDUALS WITH VS WITHOUT ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | University of South Florida Tampa, FL | A | $201,250 | paid | BIN1 IN MICROGLIAL HETEROGENEITY ALONG AD PROGRESSION AND MICROGLIAL FUNCTION | 202641319349301469 |
| 2025 | University of Texas Health Science Center at San Antonio San Antonio, TX | A | $201,250 | paid | COGNITIVELY HEALTHY NONAGENARIANS IN THE CROSS COHORT COLLABORATION (CCC) | 202641319349301469 |
| 2025 | Columbia University New York, NY | A | $201,250 | paid | SEMAPHORIN REGULATION OF DISEASE-ASSOCIATED MICROGLIA IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Regents of the University of California San Diego La Jolla, CA | A | $201,250 | paid | DYSREGULATION OF SIGNALING ON POST SYNAPTIC DENSITY SCAFFOLDS IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Emory University Atlanta, GA | A | $201,250 | paid | MITOCHONDRIAL ALZHEIMER'S RISK FACTORS CONTROL APOE EXPRESSION AND SECRETION | 202641319349301469 |
| 2025 | Johns Hopkins University Baltimore, MD | A | $201,250 | paid | FROM MOLECULAR HETEROGENEITY TO PREDICTIVE MEDICINE: TRANSFORMING NEURODEGENERATIVE DISEASE RESEARCH THROUGH SPATIAL MULTI-OMICS AND INTERPRETABLE AI | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $201,250 | paid | SPECIFICITY OF T CELL RESPONSES IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE (ADAD) | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | PRECISION GENE THERAPY TARGETING MICROGLIA IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Northwestern University Chicago, IL | A | $201,250 | paid | SEX-SPECIFIC MECHANISMS OF NEUROINFLAMMATION IN THE ALZHEIMER'S DISEASE HYPOTHALAMUS | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $201,250 | paid | THE JEFFREY L. MORBY PRIZE | 202641319349301469 |
| 2025 | The Regents of the University of California San Francisco San Francisco, CA | A | $201,250 | paid | NEURONAL MECHANISMS DRIVING SYNAPSE LOSS IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | University of California Davis Davis, CA | A | $201,250 | paid | DECIPHERING PHOSPHORYLATION-DEPENDENT TAU ENVELOPE DYSFUNCTION TO PREVENT ALZHEIMER'S NEURODEGENERATION | 202641319349301469 |
| 2025 | Icahn School of Medicine at Mount Sinai New York, NY | A | $201,250 | paid | INVESTIGATING MEF2C TRANSCRIPTION FACTOR AS THERAPEUTIC TARGET TO REPROGRAM PATHOLOGICAL MICROGLIAL STATES IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Icahn School of Medicine at Mount Sinai New York, NY | A | $201,235 | paid | RESTORING BRAIN COLLECTION IN NEW YORK CITY THROUGH THE MOUNT SINAI NEUROPATHOLOGY BRAIN BANK | 202641319349301469 |
| 2025 | Brigham and Women's Hospital Boston, MA | A | $201,234 | paid | T CELL MODULATION OF MICROGLIA TO TREAT ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $201,212 | paid | NEUROPROTECTIVE T CELL-BASED THERAPY FOR ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Houston Methodist Research Institute (houston Methodist Hospital Foundation Houston, TX | A | $201,167 | paid | A MUTI-MODALITY STUDY ON LIPID MOLECULAR BASIS OF OBESITY AND ITS ROLES IN REGULATING ALZHEIMER'S PATHOGENESIS FOR DEVELOPING POTENTIAL TARGETED INTERVENTIONS | 202641319349301469 |
| 2025 | University of Massachusetts Chan Medical School Worcester, MA | A | $200,568 | paid | VENTRICULAR EPENDYMAL CELLS: A NOVEL NEURAL-IMMUNE SIGNALING AXIS DURING AGING AND NEURODEGENERATION | 202641319349301469 |
| 2025 | Weill Medical College of Cornell University New York, NY | A | $200,532 | paid | HYPERTENSION, TAU AND NEURODEGENERATION | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $200,530 | paid | MULTIOMIC AND FUNCTIONAL CHARACTERIZATION OF STREM2 MODIFIERS | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $200,416 | paid | CIRCADIAN PERTURBATIONS OF THE VASCULOME AND MICROGLIOME IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | University of Kentucky Lexington, KY | A | $200,187 | paid | LOWERING MICROGLIAL LIPID BURDEN VIA PLIN2 MODULATION IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | University of Washington Seattle, WA | A | $200,043 | paid | ELUCIDATING THE THERAPEUTIC POTENTIAL OF THE ENDO-LYSOSOME PATHWAY FOR ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $199,281 | paid | CIRCADIAN DESYNCHRONY, GLIAL DYSFUNCTION, AND ALZHEIMER DISEASE PATHOGENESIS | 202641319349301469 |
| 2025 | Stanford University Redwood City, CA | A | $198,370 | paid | OLIGODENDROGLIAL DYNAMICS AND MYELINATION IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Stanford University Redwood City, CA | A | $198,253 | paid | BMP LIPID METABOLISM AS A THERAPEUTIC TARGET FOR LYSOSOMAL FUNCTION AND ALZHEIMER'S DISEASE PATHOGENESIS | 202641319349301469 |
| 2025 | University of California Los Angeles Los Angeles, CA | A | $191,463 | paid | NOVEL AI DECODES AGING NEURONS | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $182,921 | paid | MAPPING THE X CHROMOSOME MULTI-OME IN ALZHEIMER'S AND PARKINSON'S DISEASE | 202641319349301469 |
| 2025 | University of Texas Health Science Center at San Antonio San Antonio, TX | A | $181,004 | paid | BRIDGING MYELIN AND VASCULAR DEMENTIA: OLIGODENDROCYTE STRESS RESPONSES IN AGEING AND CEREBROVASCULAR DISEASE | 202641319349301469 |
| 2025 | Seattle Neurosound Solutions Seattle, WA | A | $175,000 | paid | CONTINUOUS MONITORING AND ENHANCEMENT OF GLYMPHATIC FLOW IN HUMAN SLEEP | 202641319349301469 |
| 2025 | Burke Neurological Institute White Plains, NY | A | $173,007 | paid | 2-DEOXYGLUCOSE AND ITS ANALOGS AS NOVEL THERAPEUTICS TO BUILD RESILIENCE TO ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | State of Maryland -University of Maryland Baltimore Baltimore, MD | U | $171,037 | paid | EXPANDING POSTMORTEM BRAIN RESOURCES FOR ALZHEIMER'S DISEASE IN DIVERSE POPULATIONS | 202641319349301469 |
| 2025 | Regents of the University of California San Diego La Jolla, CA | A | $150,937 | paid | THE ROLE OF PLANAR CELL POLARITY PROTEINS IN TAU OLIGOMER-INDUCED SYNAPSE DEGENERATION | 202641319349301469 |
| 2025 | Icahn School of Medicine at Mount Sinai New York, NY | A | $150,786 | paid | ALZHEIMER'S DISEASE PET IMAGING OF NONFIBRILLAR AMYLOID BETA AGGREGATES USING AZAPEPTIDE (AZP) TRACER | 202641319349301469 |
| 2025 | Johns Hopkins University Baltimore, MD | A | $143,697 | paid | BRIDGE FUNDING FOR A YOUNGER DIVERSE HUMAN BRAIN BANK TO INVESTIGATE EARLY AD PATHOLOGY | 202641319349301469 |
| 2025 | Baylor College of Medicine Houston, TX | A | $138,000 | paid | DECIPHER THE ASTROCYTE CELL-SURFACE PROTEOME IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $124,653 | paid | CHARACTERIZATION OF ALZHEIMER'S DISEASE MOLECULAR BIOMARKER PROFILES THROUGHOUT THE PATHOBIOLOGICAL CONTINUUM | 202641319349301469 |
| 2025 | Icahn School of Medicine at Mount Sinai New York, NY | A | $115,000 | paid | CROSS-SPECIES ANALYSIS OF MICROGLIAL STATES IN HETEROGENEOUS ALZHEIMER'S DISEASE PROGRESSION | 202641319349301469 |
| 2025 | University of Michigan Ann Arbor, MI | A | $103,168 | paid | NON-INVASIVE DELIVERY OF IL-2 TO THE CNS FOR LOCAL EXPANSION OF TREGS AND PREVENTION OF NEURODEGENERATION IN TAUOPATHY | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $100,625 | paid | CHARACTERIZATION AND OPTIMIZATION OF CNS-PENETRANT HDAC11-SELECTIVE INHIBITORS IN ALZHEIMER'S DISEASE MODELS | 202641319349301469 |
| 2025 | University of Pittsburgh Pittsburgh, PA | A | $100,625 | paid | AN ENGINEERED PLATFORM TO MODEL THE YOLK SAC-BRAIN INTERACTIONS IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Trustees of Tufts College DBA Tufts University Medford, MA | A | $100,625 | paid | ELUCIDATING THE INTERPLAY BETWEEN AD GENETIC VARIANTS USING HUMAN IPSC-DERIVED MICROGLIA-LIKE CELLS | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $100,625 | paid | AN ENGINEERED PLATFORM TO MODEL THE YOLK SAC-BRAIN INTERACTIONS IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $100,600 | paid | ELUCIDATING THE INTERPLAY BETWEEN AD GENETIC VARIANTS USING HUMAN IPSC-DERIVED MICROGLIA-LIKE CELLS | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $98,083 | paid | NON-INVASIVE DELIVERY OF IL-2 TO THE CNS FOR LOCAL EXPANSION OF TREGS AND PREVENTION OF NEURODEGENERATION IN TAUOPATHY | 202641319349301469 |
| 2025 | St Jude Children's Research Hospital Memphis, TN | A | $92,000 | paid | DECIPHER THE ASTROCYTE CELL-SURFACE PROTEOME IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | New York Genome Center New York, NY | A | $86,250 | paid | CROSS-SPECIES ANALYSIS OF MICROGLIAL STATES IN HETEROGENEOUS ALZHEIMER'S DISEASE PROGRESSION | 202641319349301469 |
| 2025 | Regents of the University of California San Diego La Jolla, CA | A | $80,500 | paid | MECHANISMS REGULATING NEUROVASCULAR FUNCTION IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Icahn School of Medicine at Mount Sinai New York, NY | A | $80,500 | paid | COMBINATORIAL ROLES OF EED AND PICALM IN MICROGLIAL CLEARANCE PATHWAYS IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | President and Fellows of Harvard College Cambridge, MA | A | $80,500 | paid | FBAT-EQUIVALENCE TESTING IN THE PRESENCE OF MODEL UNCERTAINTY FOR THE CURE ALZHEIMERS GENOME PROJECT | 202641319349301469 |
| 2025 | Boston Children's Hospital Boston, MA | A | $80,500 | paid | HOW BODY-BRAIN INFLAMMATORY SIGNALS VIA BORDER MACROPHAGES ALTER THE NEUROIMMUNE LANDSCAPE AND DRIVE ALZHEIMER'S PATHOLOGY | 202641319349301469 |
| 2025 | Weill Medical College of Cornell University New York, NY | A | $80,500 | paid | MICROGLIAL-ASTROCYTIC MECHANISMS OF APOE3 CHRISTCHURCH-MEDIATED RESILIENCE TO TAUOPATHY | 202641319349301469 |
| 2025 | New York University School of Medicine New York, NY | A | $80,500 | paid | ASTROCYTE NETWORK STRUCTURE AND FUNCTION IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | National Institute of Neurological Disorders & Stroke Bethesda, MD | A | $80,500 | paid | DYNAMIC INVESTIGATION OF LYMPHATIC PATHWAY INTERCONNECTIONS FOR CEREBROSPINAL FLUID CLEARANCE OF THE HUMAN CENTRAL NERVOUS SYSTEM IN VIVO UNDER PHYSIOLOGICAL CONDITIONS OF THE BRAIN'S BORDERS | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $80,500 | paid | SLEEP AUGMENTATION REINFORCES NEURAL COMPUTATION, ENHANCES COGNITION, AND MITIGATES NEURODEGENERATIVE DISEASE SYMPTOMS | 202641319349301469 |
| 2025 | The Regents of the University of California San Francisco San Francisco, CA | A | $80,500 | paid | DEFINE ADGRG1-MEDIATED PROTECTIVE MICROGLIAL RESPONSE TO TAU TANGLES IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | University of Kentucky Lexington, KY | A | $78,090 | paid | ASSESSING THE ROLE OF APOE IN GLIAL LIPID DROPLET METABOLISM AND FUNCTION | 202641319349301469 |
| 2025 | Washington University in St Louis St Louis, MO | A | $77,709 | paid | SUPPRESSING NEUROINFLAMMATION WITH A TARGETED PROTEIN DEGRADATION STRATEGY IN A TAUOPATHY MOUSE MODEL | 202641319349301469 |
| 2025 | University of Southern California Los Angeles, CA | A | $57,500 | paid | NEURAL STEM CELL REJUVENATION FOR SYMPTOMATIC ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Houston Methodist Research Institute (houston Methodist Hospital Foundation Houston, TX | A | $57,500 | paid | CANCER-DERIVED EXTRACELLULAR VESICLE MICRORNAS AS SYSTEMIC MODULATORS OF ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Boston Children's Hospital Boston, MA | A | $57,500 | paid | TRACKING INFLAMMATION AND REPAIR AT THE CHOROID PLEXUS IN ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Maryland Medical Legal Foundation Baltimore, MD | A | $57,500 | paid | BRIDGE FUNDING FOR A YOUNGER DIVERSE HUMAN BRAIN BANK TO INVESTIGATE EARLY AD PATHOLOGY | 202641319349301469 |
| 2025 | Northwestern University Chicago, IL | A | $57,500 | paid | ROLE OF ANNEXIN A6-MEDIATED MEMBRANE REPAIR IN ALZHEIMER'S PATHOLOGY | 202641319349301469 |
| 2025 | University of Virginia Charlottesville, VA | A | $50,312 | paid | THE ROLE OF PLANAR CELL POLARITY PROTEINS IN TAU OLIGOMER-INDUCED SYNAPSE DEGENERATION | 202641319349301469 |
| 2025 | President and Fellows of Harvard College Cambridge, MA | A | $38,944 | paid | PRECISION MEDICINE PREDICTION MODEL FOR ALZHEIMER'S DISEASE USING COOPERATIVE LEARNING APPROACHES FOR MULTI-OMIC DATA (SUPPLEMENT) | 202641319349301469 |
| 2025 | University of Miami Atlanta, GA | A | $24,589 | paid | 2-DEOXYGLUCOSE AND ITS ANALOGS AS NOVEL THERAPEUTICS TO BUILD RESILIENCE TO ALZHEIMER'S DISEASE | 202641319349301469 |
| 2025 | Massachusetts Institute of Technology Cambridge, MA | A | $9,752 | paid | DISSECTING MICROGLIAL STATE DYNAMICS IN ALZHEIMER'S DISEASE (SUPPLEMENT) | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $8,533 | paid | ALZHEIMER'S DISEASE TAU CONSORTIUM: TOXIC CONSEQUENCES OF EARLY TAU SEEDING (SUPPLEMENT) | 202641319349301469 |
| 2025 | Massachusetts General Hospital Boston, MA | A | $4,025 | paid | ROLE OF CD8+ T CELL-GLIAL INTERACTIONS IN MEDIATING ALZHEIMER'S DISEASE PATHOGENESIS (SUPPLEMENT) | 202641319349301469 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $1,955,000 | paid | THE CUREALZ ALZHEIMER'S GENOME PROJECT | 202531289349302248 |
| 2024 | Brigham and Women's Hospital Boston, MA | A | $575,000 | paid | APOE: APOE4 ACCELERATES CD8 EXHAUSTION VIA GLUCOCORTICOID SIGNALING IN ALZHEIMER'S FEMALE CARRIERS | 202531289349302248 |
| 2024 | Weill Medical College of Cornell University New York, NY | A | $402,500 | paid | SEX-BIASED TLR7 SIGNALING IN DEMYELINATION AND ITS INHIBITION BY SMALL MOLECULES | 202531289349302248 |
| 2024 | Washington University in St Louis St Louis, MO | A | $345,000 | paid | APOE: INVESTIGATING POTENTIAL CELL AUTONOMOUS NEUROPROTECTION OF APOE PROTECTIVE VARIANTS | 202531289349302248 |
| 2024 | Northwestern University Chicago, IL | A | $345,000 | paid | MBC: INTERACTION OF THE MICROBIOME WITH ASTROCYTES AND AMYLOID PATHOLOGY | 202531289349302248 |
| 2024 | Washington University in St Louis St Louis, MO | A | $345,000 | paid | BEE: MENINGEAL MAST CELL CONTROL OF CSF DYNAMICS IN HOMEOSTASIS AND ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Massachusetts Institute of Technology Cambridge, MA | A | $300,000 | paid | DISSECTING MICROGLIAL STATE DYNAMICS IN ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $300,000 | paid | UNDERSTANDING HUMAN BRAIN RESILIENCE TO ALZHEIMER'S PATHOLOGY | 202531289349302248 |
| 2024 | University of Rochester Rochester, NY | A | $287,500 | paid | BEE: DOES SLYM FAILURE COMPROMISE GLYMPHATIC CLEARANCE IN ALZHEIMER'S DISEASE? | 202531289349302248 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $287,500 | paid | MBC: MICROBIAL PROFILING OF HUMAN BRAIN AND GUT MICROBIOMES IN ALZHEIMER'S DISEASE. | 202531289349302248 |
| 2024 | University of California San Diego La Jolla, CA | A | $287,500 | paid | BEE: HOW DOES VASCULAR FATTY ACID METABOLISM REGULATE THE PATHOPHYSIOLOGY OF ALZHEIMER'S DISEASE? | 202531289349302248 |
| 2024 | New York University School of Medicine New York, NY | A | $287,500 | paid | NEUROIMMUNE CONSORTIUM: ASTROCYTE INFLAMMATORY CONTRIBUTIONS TO ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $287,500 | paid | ALZHEIMER'S DISEASE TAU CONSORTIUM: TOXIC CONSEQUENCES OF EARLY TAU SEEDING | 202531289349302248 |
| 2024 | Washington University in St Louis St Louis, MO | A | $287,500 | paid | MBC: THE ROLE OF GUT MICROBIAL METABOLISM IN TAU-MEDIATED NEURODEGENERATION | 202531289349302248 |
| 2024 | National Institute of Neurological Disorders & Stroke Bethesda, MD | A | $287,500 | paid | BEE: HIGH-RESOLUTION MRI OF THE BRAIN BORDERS | 202531289349302248 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $287,500 | paid | BEE: HUMAN 3D NEURO-VASCULAR INTERACTION AND MENINGEAL LYMPHATICS MODELS WITH APPLICATION TO ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | University of Texas Southwestern Medical Center Dallas, TX | A | $287,276 | paid | ALZHEIMER'S DISEASE TAU CONSORTIUM: STRAIN REPLICATION IN MOUSE AND CELL MODELS | 202531289349302248 |
| 2024 | Northwestern University Chicago, IL | A | $286,559 | paid | ALZHEIMER'S DISEASE TAU CONSORTIUM: THE ROLE OF AB - INDUCED MEMBRANE DAMAGE IN TAU PATHOLOGY | 202531289349302248 |
| 2024 | University of Pennsylvania Philadelphia, PA | A | $285,952 | paid | APOE: CELL AUTONOMOUS ROLES OF PROTECTIVE APOE VARIANTS IN MICROGLIA RESPONDING TO AMYLOID PATHOLOGY | 202531289349302248 |
| 2024 | University of California Davis Davis, CA | A | $285,851 | paid | NEUROIMMUNE CONSORTIUM: IMPACT OF AD POLYGENIC RISK SCORE ON MICROGLIAL RESPONSE TO PERIPHERAL INFLAMMATION | 202531289349302248 |
| 2024 | Brigham and Women's Hospital Boston, MA | A | $275,500 | paid | MBC: HARNESSING DIET-MICROBE INTERACTIONS TO PREVENT ALZHEIMER'S DISEASE PATHOGENESIS | 202531289349302248 |
| 2024 | Duke University School of Medicine Durham, NC | A | $268,750 | paid | PLASMA PROTEINS, SEX AND ALZHEIMER'S DIEASE: PROTEOMEWIDE ANALYSES OF THE UK BIOBANK AND FRAMINGHAM HEART STUDY | 202531289349302248 |
| 2024 | Washington University in St Louis St Louis, MO | A | $258,750 | paid | DISSECTING ALZHEIMER'S DISEASE PHENOTYPES IN DIRECTLY REPROGRAMMED PATIENT-DERIVED NEURONS | 202531289349302248 |
| 2024 | The University of Chicago Chicago, IL | A | $250,000 | paid | MICROBIOME CONSORTIUM: TEMPORAL RELATIONSHIPS BETWEEN GUT DYSBIOSIS, BRAIN AB METABOLISM AND MICROGLIA CELL ACTIVATION FOLLOWING ANTIBIOTIC TREATMENT | 202531289349302248 |
| 2024 | The Broad Institute Inc Cambridge, MA | A | $230,000 | paid | INVESTIGATING ALZHEIMER'S DISEASE-ASSOCIATED MEMBRANE BIOLOGY IN MICROGLIA AND NEURONS | 202531289349302248 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $230,000 | paid | SELECTIVE VULNERABILITY IN POSTERIOR CORTICAL ATROPHY | 202531289349302248 |
| 2024 | University of California Irvine Irvine, CA | A | $230,000 | paid | ENDOGENOUS HUMAN ANTIBODIES ASSOCIATED WITH ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $230,000 | paid | ADAM10 CLEAVAGE OF APP: PHYSIOLOGICAL FUNCTION IN BRAIN AND THERAPEUTIC POTENTIAL FOR ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Memorial Sloan Kettering Cancer Center New York, NY | A | $230,000 | paid | THE ROLE OF IFITM3 AND -SECRETASE IN MICROGLIA | 202531289349302248 |
| 2024 | President and Fellows of Harvard College Cambridge, MA | A | $230,000 | paid | HARVARD T.H. CHAN SCHOOL OF PUBLIC HEALTH-MOVING THE CURE ALZHEIMER GENOME PROJECT BEYOND SIMPLE ASSOCIATIONS: INTEGRATING FUNCTIONAL INFORMATION, FINE-MAPPING AND CAUSAL INFERENCE APPROACHES INTO THE FAMILY-BASED ANALYSIS OF THE CURE ALZHEIMER WHOLE-GENOME SEQUENCING (WGS) FAMILY STUDY | 202531289349302248 |
| 2024 | Brigham and Women's Hospital Boston, MA | A | $228,779 | paid | DO CLASSICAL COMPLEMENT ACTIVATION AND THE ROUTE OF ADMINISTRATION OF ANTI-AMYLOID ANTIBODIES CONTRIBUTE TO VASCULAR SIDE EFFECTS KNOWN AS ARIA? | 202531289349302248 |
| 2024 | University of Southern California Los Angeles, CA | A | $227,410 | paid | PROTECTION AGAINST ALZHEIMER'S WITH LONGEVITY-PROMOTING INTERVENTION 17A-ESTRADIOL | 202531289349302248 |
| 2024 | Washington University in St Louis St Louis, MO | A | $219,578 | paid | MAPPING THE X CHROMOSOME MULTI-OME IN ALZHEIMER'S AND PARKINSON'S DISEASE | 202531289349302248 |
| 2024 | The University of Chicago Chicago, IL | A | $216,287 | paid | IDENTIFYING THE SEX-SPECIFIC ROLES OF THE GUTMICROBIOME-BRAIN AXIS IN A MOUSE MODEL OF AB AMYLOIDOSIS | 202531289349302248 |
| 2024 | Columbia University New York, NY | A | $201,279 | paid | NEUROPROTEASOMES MECHANISTICALLY CONNECT APOE ISOFORMS TO ENDOGENOUS TAU AGGREGATION | 202531289349302248 |
| 2024 | Gladstone Institutes San Francisco, CA | A | $201,250 | paid | UNDERSTANDING HOW HUMAN BRAIN VASCULAR CELLS MEDIATE GENETIC RISK FOR ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | The Regents of the University of California San Francisco San Francisco, CA | A | $201,250 | paid | ROLE OF THE CIRCULATING EXERKINE GPLD1 IN AMELIORATING ALZHEIMER'S DISEASE PATHOLOGY | 202531289349302248 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | ROLE OF RIN3 AND BIN1 INTERACTION IN THE NEURONS FOR ALZHEIMER'S DISEASE DEVELOPMENT | 202531289349302248 |
| 2024 | Stanford University Redwood City, CA | A | $201,250 | paid | MULTIOMICS CHARACTERIZATION OF TAU PATHOLOGY ONSET AND ITS RELATIONSHIP WITH AMYLOID IN THE HUMAN HIPPOCAMPUS | 202531289349302248 |
| 2024 | The University of Texas Health Science Center at San Antonio San Antonio, TX | A | $201,250 | paid | IDENTIFICATION AND VALIDATION OF PLASMA-BASED LIPID BIOMARKERS FOR EARLY ALZHEIMER'S DISEASE IN THE UNIQUE, PRIMARILY HISPANIC, SOUTH TEXAS POPULATION | 202531289349302248 |
| 2024 | Washington University in St Louis St Louis, MO | A | $201,250 | paid | CONTRIBUTION OF SKULL BONE MARROW-DERIVED CELLS TO ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | GROWTH, CHARACTERIZATION, AND DISTRIBUTION OF A NEURODEGENERATIVE DISEASE-FOCUSED FIBROBLAST/IPS CELL BANK TO SUPPORT MOLECULAR MODELS OF PATIENT-SPECIFIC VARIATION WITH VALIDATION IN MATCHED DONATED BRAIN TISSUES | 202531289349302248 |
| 2024 | President and Fellows of Harvard College Cambridge, MA | A | $201,250 | paid | HARVARD MEDICAL SCHOOL-MENINGEAL TREGS IN INDIVIDUALS WITH VS WITHOUT ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | The Salk Institute for Biological Studies La Jolla, CA | A | $201,250 | paid | THE ROLE OF ASTROCYTE-SECRETED LGFBP2 IN THE PROGRESSION OF ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | President and Fellows of Harvard College Cambridge, MA | A | $201,250 | paid | HARVARD MEDICAL SCHOOL-DEFINING A ROLE FOR THE MS4A GENES IN ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | TAU AND B-AMYLOID ARE INNATE IMMUNE ANTIMICROBIAL PEPTIDES IN THE BRAIN | 202531289349302248 |
| 2024 | University of Washington Seattle, WA | A | $201,250 | paid | ELUCIDATING THE THERAPEUTIC POTENTIAL OF THE ENDOLYSOSOME PATHWAY FOR ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Weill Medical College of Cornell University New York, NY | A | $201,250 | paid | TAU-INDUCED POSTSYNAPTIC DYSFUNCTION IN TAUOPATHY MODELS | 202531289349302248 |
| 2024 | Icahn School of Medicine at Mount Sinai New York, NY | A | $201,250 | paid | INVESTIGATING LYSOSOMAL MECHANISMS OF RISK AND RESILIENCE IN ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | President and Fellows of Harvard College Cambridge, MA | A | $201,250 | paid | HARVARD MEDICAL SCHOOL-DISSECTING THE MODULATORY ROLES OF IL-17RD IN ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | University of Rhode Island Kingston, RI | A | $201,250 | paid | EFFECT OF APOE GENOTYPE IN A NOVEL RAT MODEL OF CEREBRAL AMYLOID ANGIOPATHY - YEAR 2/2 | 202531289349302248 |
| 2024 | Washington University in St Louis St Louis, MO | A | $201,250 | paid | DEVELOPMENT OF SMALL MOLECULE INHIBITORS OF CHOLESTEROL 25-HYDROXYLASE | 202531289349302248 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | ROLE OF STABILIZATION OF MAMS AND MAM-ASSOCIATED PALMITOYLATED APP (MAM-PALAPP) IN ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | CHARACTERIZING GUT BACTERIOME-MYCOBIOME SYNERGY IN CORRELATION TO AMYLIN-AB ANTIMICROBIAL SYNERGY IN ALZHEIMER'S DISEASE (AD) IN AD MOUSE MODELS | 202531289349302248 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | CHARACTERIZATION OF CNS-PENETRANT HDAC 11 SELECTIVE INHIBITORS IN ALZHEIMER'S DISEASE MODELS | 202531289349302248 |
| 2024 | Washington University in St Louis St Louis, MO | A | $201,250 | paid | 2024 MORBY PRIZE | 202531289349302248 |
| 2024 | The Salk Institute for Biological Studies La Jolla, CA | A | $201,250 | paid | TO ELUCIDATE THE ROLE OF MEMORY T CELLS AS A DETERMINANT OF AGE-RELATED INFLAMMATION IN ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | University of Virginia Charlottesville, VA | A | $201,250 | paid | IMPACT OF DNA DAMAGE-MEDIATED STING ACTIVATION ON MYELIN FUNCTION IN AN ALZHEIMER'S DISEASE ANIMAL MODEL | 202531289349302248 |
| 2024 | Weill Medical College of Cornell University New York, NY | A | $201,250 | paid | IDENTIFICATION AND DEVELOPMENT OF CD33 INHIBITORS AND PRE-RNA SPLICING MODULATORS | 202531289349302248 |
| 2024 | Mayo Clinic Jacksonville Jacksonville, FL | A | $201,250 | paid | EVALUATING THE CONTRIBUTION OF TDP-43 DYSFUNCTION AND CRYPTIC MIS-SPLICING TO AD PATHOGENESIS | 202531289349302248 |
| 2024 | Icahn School of Medicine at Mount Sinai New York, NY | A | $201,250 | paid | INVESTIGATING THE ASSOCIATION BETWEEN CLONAL HEMATOPOIESIS AND ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Washington University in St Louis St Louis, MO | A | $201,250 | paid | ANTIVIRAL T CELL INFILTRATION TO THE MENINGES AND BRAIN INFLUENCES NEURODEGENERATION IN ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Washington University in St Louis St Louis, MO | A | $201,250 | paid | IDENTIFYING AGE-RELATED PROTEOMIC CHANGES THAT PREDICT FUTURE ONSET OF AMYLOID-BETA AGGREGATION IN LATE ONSET ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | The Regents of the University of California San Francisco San Francisco, CA | A | $201,250 | paid | PROBING THE MOLECULAR UNDERPINNINGS OF G PROTEIN-COUPLED RECEPTOR ADGRG1 MEDIATED PROTECTIVE MICROGLIAL RESPONSES TO ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | New York University School of Medicine New York, NY | A | $201,250 | paid | MIDLIFE AUTOANTIBODY PROFILES AND THE RISK OF LATE ONSET ALZHEIMER'S DISEASE IN WOMEN | 202531289349302248 |
| 2024 | Icahn School of Medicine at Mount Sinai New York, NY | A | $201,250 | paid | ROLE OF PSYCHOSOCIAL STRESS IN ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | EXPLORING NOVEL DRUG CANDIDATES FOR ALZHEIMER'S DISEASE THROUGH INTEGRATIVE PATHWAY ANALYSIS AND VALIDATION IN 3D CELLULAR MODELS | 202531289349302248 |
| 2024 | Carnegie Mellon University Pittsburgh, PA | A | $201,250 | paid | INTERPRETING ALZHEIMER'S DISEASE-ASSOCIATED GENETIC VARIATION AT ENHANCER REGIONS | 202531289349302248 |
| 2024 | Mayo Clinic Jacksonville Jacksonville, FL | A | $201,250 | paid | RESTORE MENINGEAL LYMPHATIC DRAINAGE TO ALLEVIATE WHITE MATTER DAMAGE AND CEREBRAL AMYLOID ANGIOPATHY IN A MODEL OF ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | University of California San Diego La Jolla, CA | A | $201,250 | paid | DYSREGULATION OF SIGNALING ON POST SYNAPTIC DENSITY SCAFFOLDS IN ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | University of Virginia Charlottesville, VA | A | $201,250 | paid | ELUCIDATING THE ROLE OF CLEC7A IN TAU-MEDIATED NEURODEGENERATIVE DISEASE | 202531289349302248 |
| 2024 | Univeristy of California Los Angeles Los Angeles, CA | A | $201,250 | paid | NOVEL AI DECODES AGING NEURONS | 202531289349302248 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | VALIDATION AND CHARACTERIZATION OF COMPOUNDS MODULATING NEUROINFLAMMATION AND AMYLOID BETA UPTAKE IN MICROGLIAL CELLS | 202531289349302248 |
| 2024 | University of California Irvine Irvine, CA | A | $201,250 | paid | BIOINFORMATICS PLATFORM FOR MODELING ALZHEIMER'S PROGRESSION (MAP-AD PLATFORM) | 202531289349302248 |
| 2024 | Washington University in St Louis St Louis, MO | A | $201,250 | paid | SPECIFICITY OF T CELL RESPONSES IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE (ADAD) | 202531289349302248 |
| 2024 | Washington University in St Louis St Louis, MO | A | $201,250 | paid | TARGETING REACTIVE ASTROCYTES AMPK SIGNALING TO SUPPRESS INFLAMMATION IN ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | ROLE OF CD8+ T CELL-GLIAL INTERACTIONS IN MEDIATING ALZHEIMER'S DISEASE PATHOGENESIS | 202531289349302248 |
| 2024 | Brigham and Women's Hospital Boston, MA | A | $201,250 | paid | ROLE OF CHECKPOINT MOLECULES TIM-3 AND LAG-3 IN MICROGLIAL FUNCTION IN ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Wake Forest University Health Sciences Winstonsalem, NC | A | $201,250 | paid | INVESTIGATING THE ROLE OF TAU PROTEIN IN NEURONAL SENESCENCE | 202531289349302248 |
| 2024 | Dana-Farber Cancer Institute Inc Boston, MA | A | $201,250 | paid | PRE-CLINICAL TESTING OF CDK4/6 INHIBITORS AS A THERAPEUTIC STRATEGY IN ALZHEIMER'S DISEASE USING AD TAUOPATHY MOUSE MODEL | 202531289349302248 |
| 2024 | Beth Israel Deadoness Medical Center Boston, MA | A | $201,235 | paid | INTEGRATING SINGLE-CELL GENOMICS FOR PATHWAYS TO PROTECTION AND RESILIENCE AGAINST ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Brigham and Women's Hospital Boston, MA | A | $201,234 | paid | T CELL MODULATION OF MICROGLIA TO TREAT ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $201,227 | paid | CIRCUIT DYNAMICS IN APOE4 MICE | 202531289349302248 |
| 2024 | Indiana University Bloomington, IN | A | $200,631 | paid | MODULATING THE LEVELS OF TAU-SEED INTERACTORS TO TREAT ALZHEIMER'S DISEASES | 202531289349302248 |
| 2024 | Weill Medical College of Cornell University New York, NY | A | $200,532 | paid | HYPERTENSION, TAU AND NEURODEGENERATION | 202531289349302248 |
| 2024 | Washington University in St Louis St Louis, MO | A | $200,356 | paid | MULTIOMIC AND FUNCTIONAL CHARACTERIZATION OF STREM2 MODIFIERS | 202531289349302248 |
| 2024 | Yale University New Haven, CT | A | $199,995 | paid | THE ROLE OF CALCIUM HOMEOSTASIS IN AXONAL SPHEROID FORMATION IN ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Brigham and Women's Hospital Boston, MA | A | $195,250 | paid | TARGETING NEUROINFLAMMATION WITH NASAL ADMINISTRATION OF ANTI-CD3 MONOCLONAL ANTIBODY TO TREAT ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Duke University School of Medicine Durham, NC | A | $192,314 | paid | CONTRIBUTIONS OF IL34 SIGNALING TO MICROGLIAL FUNCTION AND ALZHEIMER'S PATHOLOGY IN MICE | 202531289349302248 |
| 2024 | President and Fellows of Harvard College Cambridge, MA | A | $187,315 | paid | HARVARD T.H. CHAN SCHOOL OF PUBLIC HEALTH-PRECISION MEDICINE PREDICTION MODEL FOR ALZHEIMER'S DISEASE USING COOPERATIVE LEARNING APPROACHES FOR MULTI-OMIC DATA | 202531289349302248 |
| 2024 | Indiana University Bloomington, IN | A | $180,419 | paid | RELATIONSHIP BETWEEN ALZHEIMER'S DISEASE RISK AND OUTCOMES OF MILD REPETITIVE NEUROTRAUMA | 202531289349302248 |
| 2024 | Burke Neurological Institute White Plains, NY | A | $173,007 | paid | 2-DEOXYGLUCOSE AND ITS ANALOGS AS NOVEL THERAPEUTICS TO BUILD RESILIENCE TO ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $172,500 | paid | NEUROPROTECTIVE EFFECTS OF THE EXERCISE HORMONE IRISIN IN ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $172,500 | paid | NEUROPROTECTIVE EFFECTS OF THE EXERCISE HORMONE IRISIN IN ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Icahn School of Medicine at Mount Sinai New York, NY | A | $172,500 | paid | VGF-DERIVED PEPTIDE THERAPY FOR AD: STUDIES OF MOUSE AND HUMAN TLQP-21 AND ITS RECEPTOR, C3AR1 | 202531289349302248 |
| 2024 | Icahn School of Medicine at Mount Sinai New York, NY | A | $150,786 | paid | ALZHEIMER'S DISEASE PET IMAGING OF NONFIBRILLAR AMYLOID BETA AGGREGATES USING AZAPEPTIDE (AZP) TRACER | 202531289349302248 |
| 2024 | University of Michigan Ann Arbor, MI | A | $148,773 | paid | NON-INVASIVE DELIVERY OF IL-2 TO THE CNS FOR LOCAL EXPANSION OF TREGS AND PREVENTION OF NEURODEGENERATION IN TAUOPATTHY | 202531289349302248 |
| 2024 | Baylor College of Medicine Houston, TX | A | $138,000 | paid | DECIPHER THE ASTROCYTE CELL-SURFACE PROTEOME IN ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $125,000 | paid | THE IMPACT OF MUTATIONS IN THE LIGAND-BINDING DOMAIN OF CD33 ON ALZHEIMER'S DISEASE PATHOGENESIS | 202531289349302248 |
| 2024 | Washington University in St Louis St Louis, MO | A | $123,098 | paid | CHARACTERIZATION OF MOLECULAR BIOMARKER PROFILES THROUGHOUT THE PATHOBIOLOGICAL CONTINUUM | 202531289349302248 |
| 2024 | St Jude Children's Research Hospital Memphis, TN | A | $92,000 | paid | DECIPHER THE ASTROCYTE CELL-SURFACE PROTEOME IN ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Boston Children's Hospital Boston, MA | A | $86,250 | paid | BEE: NEUROINFLAMMATION AT THE CHOROID PLEXUS IN ALZHEIMER'S DISEASE - SUPPLEMENT TO YR 1 (OF2) | 202531289349302248 |
| 2024 | Washington University in St Louis St Louis, MO | A | $52,477 | paid | NON-INVASIVE DELIVERY OF IL-2 TO THE CNS FOR LOCAL EXPANSION OF TREGS AND PREVENTION OF NEURODEGENERATION IN TAUOPATTHY | 202531289349302248 |
| 2024 | Duke University School of Medicine Durham, NC | A | $24,957 | paid | UTILITY OF BLOOD BASED MARKERS FOR PREDICTING ARIA AND ITS COURSE IN MCI AND AD SUBJECTS UNDERGOING ROUTINE CLINICAL TREATMENT WITH AMYLOID-DIRECTED ANTIBODIES | 202531289349302248 |
| 2024 | University of Miami Atlanta, GA | A | $24,589 | paid | 2-DEOXYGLUCOSE AND ITS ANALOGS AS NOVEL THERAPEUTICS TO BUILD RESILIENCE TO ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Medical College of Wisconsin Milwaukee, WI | A | $4,721 | paid | RELATIONSHIP BETWEEN ALZHEIMER'S DISEASE RISK AND OUTCOMES OF MILD REPETITIVE NEUROTRAUMA | 202531289349302248 |
| 2023 | Massachusetts General Hospital Boston, MA | A | $1,955,000 | paid | THE CUREALZ ALZHEIMER'S GENOME PROJECT | 202421229349300027 |
| 2023 | Brigham and Women's Hospital Boston, MA | A | $431,250 | paid | A NEW MODEL OF MICROGLIA GENETIC PERTURBATION IN VIVO TO SCREEN ALL RISK FACTORS ASSOCIATED WITH ALZHEIMER'S DISEASE | 202421229349300027 |
| 2023 | Massachusetts General Hospital Boston, MA | A | $345,000 | paid | NEUROPROTECTIVE EFFECTS OF THE EXERCISE HORMONE IRISIN IN ALZHEIMER'S DISEASE | 202421229349300027 |
| 2023 | Washington University St Louis, MO | A | $345,000 | paid | APOE CONSORTIUM: ROLE OF APOE ISOFORMS IN IMMUNE RESPONSES IN A MODEL OF TAUOPATHY | 202421229349300027 |
| 2023 | Northwestern University Chicago, IL | A | $345,000 | paid | MBC: INTERACTION OF THE MICROBIOME WITH ASTROCYTES AND AMYLOID PATHOLOGY | 202421229349300027 |
| 2023 | Washington University St Louis, MO | A | $345,000 | paid | BEE: CROSSTALK OF CNS BARRIERS AND CLEARANCE ROUTES IN HOMEOSTASIS AND ALZHEIMER'S DISEASE | 202421229349300027 |
| 2023 | Boston Children's Hospital Boston, MA | A | $344,085 | paid | NIC: EFFECTS OF PERIPHERAL INFLAMMATION ON MYELOID CELL FUNCTION IN ALZHEIMER'S DISEASE | 202421229349300027 |
| 2023 | University of Southern California Los Angeles, CA | A | $301,069 | paid | AIR POLLUTION AND AD RISK INTERACT WITH PREMATURE AGING OF NEURAL STEM CELLS AND APOE ALLELES | 202421229349300027 |
| 2023 | Massachusetts General Hospital Boston, MA | A | $300,000 | paid | UNDERSTANDING HUMAN BRAIN RESILIENCE TO ALZHEIMER'S PATHOLOGY | 202421229349300027 |
| 2023 | Massachusetts Institute of Technology Cambridge, MA | A | $300,000 | paid | CIRCUITS: DISSECTING MICROGLIAL STATE DYNAMICS IN ALZHEIMER'S DISEASE | 202421229349300027 |
| 2023 | Boston University Boston, MA | A | $287,500 | paid | APOE CONSORTIUM: MODULATION OF SELECTIVE NEURONAL VULNERABILITY IN ALZHEIMER'S DISEASE BY APOE | 202421229349300027 |
| 2023 | University of California San Diego La Jolla, CA | A | $287,500 | paid | NIC: MECHANISMS MEDIATING MICROGLIA SENSING OF PERIPHERAL INFLAMMATION | 202421229349300027 |
| 2023 | Weill Cornell New York, NY | A | $287,500 | paid | BEE: BIOCHEMICAL AND FUNCTIONAL ANALYSIS OF CSF AND LYMPH FOLLOWING CHANGES IN BRAIN FLUID DYNAMICS | 202421229349300027 |
| 2023 | Brigham and Women's Hospital Boston, MA | A | $287,500 | paid | APOE CONSORTIUM: APOE4-MEDIATED DYSFUNCTION OF CD8 T CELL-MICROGLIA CROSSTALK IN ALZHEIMER'S DISEASE | 202421229349300027 |
| 2023 | Massachusetts General Hospital Boston, MA | A | $287,500 | paid | MBC: MICROBIAL PROFILING OF HUMAN BRAIN AND GUT MICROBIOMES IN ALZHEIMER'S DISEASE | 202421229349300027 |
| 2023 | Brigham and Women's Hospital Boston, MA | A | $287,500 | paid | MBC: HARNESSING DIET-MICROBE INTERACTIONS TO PREVENT ALZHEIMER'S DISEASE PATHOGENESIS | 202421229349300027 |
| 2023 | University of California San Diego La Jolla, CA | A | $287,500 | paid | BEE: IDENTIFYING THE BLOOD-BRAIN BARRIER CHANGES DURING ALZHEIMER'S DISEASE | 202421229349300027 |
| 2023 | Washington University St Louis, MO | A | $287,500 | paid | MBC: THE ROLE OF GUT MICROBIAL METABOLISM IN TAU-MEDIATED NEURODEGENERATION | 202421229349300027 |
| 2023 | University of California Irvine Irvine, CA | A | $287,493 | paid | NIC: EXAMINING THE IMPACT OF PERIPHERALLY DERIVED HUMAN MACROPHAGES IN AD PATHOGENESIS | 202421229349300027 |
| 2023 | Massachusetts General Hospital Boston, MA | A | $287,169 | paid | ADTC: HOW DO SOLUBLE TAU SPECIES REPLICATE? | 202421229349300027 |
| 2023 | University of Texas Southwestern Medical Center Dallas, TX | A | $287,000 | paid | ADTC: ROLE OF VCP/P97 IN TAU PRION REPLICATION | 202421229349300027 |
| 2023 | Northwestern University Chicago, IL | A | $286,448 | paid | ADTC: THE ROLE OF A-INDUCED MEMBRANE DAMAGE IN TAU PATHOLOGY | 202421229349300027 |
| 2023 | Massachusetts General Hospital Boston, MA | A | $258,750 | paid | FUNCTIONAL CHANGES TO CEREBROSPINAL FLUID IMMUNE CELLS RESULTING FROM BACILLUS CALMETTE-GURIN (BCG) VACCINATION IN OLDER ADULTS WITH AND WITHOUT ALZHEIMER'S DISEASE | 202421229349300027 |
| 2023 | University of Chicago Chicago, IL | A | $250,000 | paid | MBC: TEMPORAL RELATIONSHIPS BETWEEN GUT DYSBIOSIS, BRAIN AB METABOLISM AND MICROGLIA CELL ACTIVATION FOLLOWING ANTIBIOTIC TREATMENT | 202421229349300027 |
| 2023 | Weill Cornell New York, NY | A | $250,000 | paid | DEVELOPMENT OF HUMAN CGAS INHIBITORS TO TREAT ALZHEIMER'S DISEASE | 202421229349300027 |
| 2023 | University of Southern California Los Angeles, CA | A | $250,000 | paid | CELLULAR AND MOLECULAR STUDIES OF APOE REGULATION OF BLOOD-BRAIN BARRIER, SYNAPTIC AND NEURONAL FUNCTIONS AND PROTECTION STRATEGIES IN MOUSE MODELS WITH AND WITHOUT ALZHEIMER'S PAHTOLOGY | 202421229349300027 |
| 2023 | University of Southern California Los Angeles, CA | A | $234,709 | paid | PROTECTION AGAINST APOE4 WITH LONGEVITY-PROMOTING INTERVENTIONS | 202421229349300027 |
| 2023 | University of Connecticut Farmington, CT | A | $230,000 | paid | AD PATHOPHYSIOLOGY ALTERS THE LEVEL OF ELECTRICAL AND CHEMICAL SYNAPSE COUPLING IN THE NETWORK OF GABAERGIC PV+ INTERNEURONS EARLY IN DISEASE COURSE | 202421229349300027 |
| 2023 | Massachusetts General Hospital Boston, MA | A | $230,000 | paid | BEE: A 3D IN-VITRO NEURO-VASCULAR HUMAN BRAIN MODEL WITH MENINGEAL LYMPHATICS FOR ELUCIDATING MECHANISMS UNDERLYING ALZHEIMER'S DISEASE | 202421229349300027 |
| 2023 | University of California Irvine Irvine, CA | A | $230,000 | paid | ENDOGENOUS HUMAN ANTIBODIES ASSOCIATED WITH ALZHEIMER'S DISEASE | 202421229349300027 |
| 2023 | University of Texas Southwestern Medical Center Dallas, TX | A | $230,000 | paid | RNA AS A DETERMINANT OF TAU SEEDING | 202421229349300027 |
| 2023 | Memorial Sloan Kettering Cancer Center New York, NY | A | $230,000 | paid | THE ROLE OF IFITM3 AND Y-SECRETASE IN MICROGLIA | 202421229349300027 |
| 2023 | University of California San Diego La Jolla, CA | A | $230,000 | paid | APP GENE DOSE-MEDIATED DYSREGULATION OF THE ENDOLYSOSOMAL NETWORK ACTS COMPROMISE SYNAPTIC STRUCTURE AND FUNCTION LEADING TO ALZHEIMER'S DISEASE IN DOWN SYNDROME | 202421229349300027 |
| 2023 | Duke University School of Medicine Durham, NC | A | $229,994 | paid | UTILITY OF BLOOD BASED MARKERS FOR PREDICTING ARIA AND ITS COURSE IN MCI AND AD SUBJECTS UNDERGOING ROUTINE CLINICAL TREATMENT WITH AMYLOID-DIRECTED ANTIBODIES | 202421229349300027 |
| 2023 | Harvard Medical School Cambridge, MA | A | $220,071 | paid | ANALYTICAL AND STATISTICAL TOOLS FOR SEQUENCE ANALYSIS FOR ALZHEIMER'S DISEASE | 202421229349300027 |
| 2023 | New York University New York, NY | A | $208,033 | paid | MECHANISMS OF ASTROCYTE-DERIVED LIPID TOXICITY IN ALZHEIMER'S DISEASE | 202421229349300027 |
| 2023 | Yale University New Haven, CT | A | $204,081 | paid | BEE: CNS FLUID HOMEOSTASIS AND WASTE CLEARANCE IN ALZHEIMER'S DISEASE CHARACTERIZED BY MRI | 202421229349300027 |
| 2023 | Columbia University New York, NY | A | $201,501 | paid | NEUROPROTEASOMES MECHANISTICALLY CONNECT APOE ISOFORMS TO ENDOGENOUS TAU AGGREGATION | 202421229349300027 |
| 2023 | Brigham and Women's Hospital Boston, MA | A | $201,250 | paid | NEUROIMMUNE CONNECTOME PERTURBATIONS IN ALZHEIMER'S DISEASE | 202421229349300027 |
| 2023 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | VALIDATION AND CHARACTERIZATION OF COMPOUNDS MODULATING NEUROINFLAMMATION AND AMYLOID BETA UPTAKE IN MICROGLIAL CELLS | 202421229349300027 |
| 2023 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | ROLE OF CD8+ T CELL-GLIAL INTERACTIONS IN MEDIATING ALZHEIMER'S DISEASE PATHOGENESIS | 202421229349300027 |
| 2023 | Emory University Atlanta, GA | A | $201,250 | paid | MITOCHONDRIAL ALZHEIMER'S RISK FACTORS CONTROL APOE EXPRESSION AND SECRETION | 202421229349300027 |
| 2023 | University of Southern California Los Angeles, CA | A | $201,250 | paid | PRENATAL INFLAMMATION EFFECTS ON BLOOD BRAIN BARRIER FUNCTION AND AD-RELATED PATHOLOGIES ACROSS THE LIFESPAN | 202421229349300027 |
| 2023 | Brigham and Women's Hospital Boston, MA | A | $201,250 | paid | ROLE OF CHECKPOINT MOLECULES TIM-3 AND LAG-3 IN MICROGLIAL FUNCTION IN ALZHEIMER'S DISEASE | 202421229349300027 |
| 2023 | Washington University St Louis, MO | A | $201,250 | paid | CONTRIBUTION OF SKULL BONE MARROW-DERIVED CELLS TO ALZHEIMER'S DISEASE | 202421229349300027 |
| 2023 | University of Michigan Ann Arbor, MI | A | $201,250 | paid | MORPHOLOGICAL, ELECTROPHYSIOLOGICAL, AND TRANSCRIPTIONAL CHARACTERIZATION OF SINGLE NEURONS FROM RESILIENT AND SUSCEPTIBLE MODELS OF HUMAN AD | 202421229349300027 |
| 2023 | Brigham and Women's Hospital Boston, MA | A | $201,250 | paid | TARGETING THE MICROBIOME AND INNATE IMMUNITY IN ALZHEIMER'S DISEASE | 202421229349300027 |
| 2023 | Mayo Clinic Jacksonville Jacksonville, FL | A | $201,250 | paid | EVALUATING TMEM106B ACCUMULATION IN AD | 202421229349300027 |
| 2023 | University of Texas Health Science Center at San Antonio San Antonio, TX | A | $201,250 | paid | IDENTIFICATION AND VALIDATION OF PLASMA-BASED LIPID BIOMARKERS FOR EARLY ALZHEIMER'S DISEASE IN THE UNIQUE, PRIMARILY HISPANIC, SOUTH TEXAS POPULATION | 202421229349300027 |
| 2023 | Mayo Clinic Jacksonville Jacksonville, FL | A | $201,250 | paid | RESTORE MENINGEAL LYMPHATIC DRAINAGE TO ALLEVIATE WHITE MATTER DAMAGE AND CEREBRAL AMYLOID ANGIOPATHY IN A MODEL OF ALZHEIMER'S DISEASE | 202421229349300027 |
| 2023 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | ROLE OF RIN3 AND BIN1 INTERACTION IN THE NEURONS FOR ALZHEIMER'S DISEASE DEVELOPMENT | 202421229349300027 |
| 2023 | University of Virginia Charlottesville, VA | A | $201,250 | paid | ELUCIDATING THE ROLE OF CLEC7A IN TAU-MEDIATED NEURODEGENERATIVE DISEASE | 202421229349300027 |
| 2023 | University of Rhode Island Kingston, RI | A | $201,250 | paid | EFFECT OF APOE GENOTYPE IN A NOVEL RAT MODEL OF CEREBRAL AMYLOID ANGIOPATHY | 202421229349300027 |
| 2023 | Brigham and Women's Hospital Boston, MA | A | $201,250 | paid | TARGETING NEUROINFLAMMATION WITH NASAL ADMINISTRATION OF ANTI-CD3 MONOCLONAL ANTIBODY TO TREAT ALZHEIMER'S DISEASE | 202421229349300027 |
| 2023 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | ROLE OF STABILIZATION OF MAMS AND MAM-ASSOCIATED PALMITOYLATED APP (MAM-PALAPP) IN ALZHEIMER'S DISEASE | 202421229349300027 |
| 2023 | Weill Cornell New York, NY | A | $201,250 | paid | IDENTIFICATION AND DEVELOPMENT OF CD33 INHIBITORS AND PRE-RNA SPLICING MODULATORS | 202421229349300027 |
| 2023 | Tufts University Boston, MA | A | $201,250 | paid | MULTIDISCIPLINARY PHENOTYPING OF A NOVEL HUMANIZED LOAD MOUSE MODEL | 202421229349300027 |
| 2023 | The Salk Institute for Biologial Studies La Jolla, CA | A | $201,250 | paid | TO ELUCIDATE THE ROLE OF MEMORY T CELLS AS A DETERMINANT OF AGE-RELATED INFLAMMATION IN ALZHEIMER'S DISEASE | 202421229349300027 |
| 2023 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | CHARACTERIZING GUT BACTERIOME-MYCOBIOME SYNERGY IN CORRELATION TO AMYLIN-A ANTIMICROBIAL SYNERGY IN ALZHEIMER'S DISEASE (AD) IN AD MOUSE MODELS | 202421229349300027 |
| 2023 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | GROWTH, CHARACTERIZATION, AND DISTRIBUTION OF A NEURODEGENERATIVE DISEASE-FOCUSED FIBROBLAST/IPS CELL BANK TO SUPPORT MOLECULAR MODELS OF PATIENT-SPECIFIC VARIATION WITH VALIDATION IN MATCHED DONATED BRAIN TISSUES | 202421229349300027 |
| 2023 | Icahn Scool of Medicine at Mount Sinai New York, NY | A | $201,250 | paid | INVESTIGATING LYSOSOMAL MECHANISMS OF RISK AND RESILIENCE IN ALZHEIMER'S DISEASE | 202421229349300027 |
| 2023 | Mayo Clinic Jacksonville Jacksonville, FL | A | $201,250 | paid | ABCA7 LOSS OF FUNCTION IN AGING AND ALZHEIMER'S DISEASE | 202421229349300027 |
| 2023 | Mayo Clinic Jacksonville Jacksonville, FL | A | $201,250 | paid | ELUCIDATING THE PROTECTIVE EFFECTS OF APOE2 IN THE PRESENCE OF APOE4 GENE ALLELE IN ANIMAL MODELS | 202421229349300027 |
| 2023 | Icahn Scool of Medicine at Mount Sinai New York, NY | A | $201,250 | paid | INVESTIGATING MEF2C TRANSCRIPTION FACTOR AS THERAPEUTIC TARGET TO REPROGRAM PATHOLOGICAL MICROGLIAL STATES IN ALZHEIMER'S DISEASE | 202421229349300027 |
| 2023 | Columbia University New York, NY | A | $201,250 | paid | NONCODING TRANSLATION FEEDBACK LOOP IN ALZHEIMER'S DISEASE | 202421229349300027 |
| 2023 | Weill Cornell New York, NY | A | $201,250 | paid | TAU-INDUCED POSTSYNAPTIC DYSFUNCTION IN TAUOPATHY MODELS | 202421229349300027 |
| 2023 | The Regents of the University of Califormia San Francisco San Francisco, CA | A | $201,250 | paid | NEURONAL MECHANISMS DRIVING SYNAPSE LOSS IN ALZHEIMER'S DISEASE | 202421229349300027 |
| 2023 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | CHARACTERIZATION OF CNS-PENETRANT HDAC11-SELECTIVE INHIBITORS IN ALZHEIMER'S DISEASE MODELS | 202421229349300027 |
| 2023 | Stanford University Redwood City, CA | A | $201,250 | paid | MULTIOMICS CHARACTERIZATION OF TAU PATHOLOGY ONSET AND ITS RELATIONSHIP WITH AMYLOID IN THE HUMAN HIPPOCAMPUS | 202421229349300027 |
| 2023 | University of Virginia Charlottesville, VA | A | $201,250 | paid | EXPLORING THE THERAPEUTIC POTENTIAL OF CLUSTERIN IN A PRECLINICAL MODEL OF ALZHEIMER'S DISEASE | 202421229349300027 |
| 2023 | Washington University St Louis, MO | A | $201,250 | paid | DISSECTING ALZHEIMER'S DISEASE PHENOTYPES IN DIRECTLY REPROGRAMMED PATIENT-DERIVED NEURONS | 202421229349300027 |
| 2023 | Johns Hopkins University Baltimore, MD | A | $201,250 | paid | HUMAN BRAIN CD33 LIGAND, RPTPS3L, LIMITS MICROGLIAL PHAGOCYTOSIS AND CONTRIBUTES TO ALZHEIMER'S DISEASE PROGRESSION | 202421229349300027 |
| 2023 | Washington University St Louis, MO | A | $201,248 | paid | ANTIVIRAL T CELLS INFILTRATION TO THE MENINGES AND BRAIN INFLUENCES NEURODEGENERATION IN ALZHEIMER'S DISEASE | 202421229349300027 |
| 2023 | The Methodist Hospital Foundation Houston, TX | A | $201,199 | paid | A MUTI-MODALITY STUDY ON LIPID MOLECULAR BASIS OF OBESITY AND ITS ROLES IN REGULATING ALZHEIMER'S PATHOGENESIS FOR DEVELOPING POTENTIAL TARGETED INTERVENTIONS | 202421229349300027 |
| 2023 | Washington University St Louis, MO | A | $198,994 | paid | CIRCADIAN DESYNCHRONY, GLIAL DYSFUNCTION, AND ALZHEIMER'S DISEASE PATHOGENESIS | 202421229349300027 |
| 2023 | Stanford University Redwood City, CA | A | $198,751 | paid | OLIGODENDROGLIAL DYNAMICS AND MYELINATION IN ALZHEIMER'S DISEASE | 202421229349300027 |
| 2023 | Duke University School of Medicine Durham, NC | A | $195,434 | paid | CONTRIBUTIONS OF IL34 SIGNALING TO MICROGLIAL FUNCTION AND ALZHEIMER'S PATHOLOGY IN MICE | 202421229349300027 |
| 2023 | University of Virginia Charlottesville, VA | A | $192,020 | paid | TOXIC EFFECTS OF EXTRACELLULAR TAU OLIGOMERS ON NEURONS | 202421229349300027 |
| 2023 | Washington University St Louis, MO | A | $189,902 | paid | DECIPHERING AND RESTORING COMPUTATIONAL SET-POINTS IN ALZHEIMER'S DISEASE THROUGH SLEEP-ENHANCED NETWORK HOMEOSTASIS | 202421229349300027 |
| 2023 | Boston Children's Hospital Boston, MA | A | $189,750 | paid | NEUROINFLAMMATION AT THE CHOROID PLEXUS IN ALZHEIMER'S DISEASE | 202421229349300027 |
| 2023 | Broad Institute Cambridge, MA | A | $172,550 | paid | REVEALING NEW GENES AND PATHWAYS AT THE INTERSECTION OF LIPOTOXIC AND GENETIC RISK FOR ALZHEIMER'S DISEASE | 202421229349300027 |
| 2023 | Washington University St Louis, MO | A | $172,500 | paid | UNDERSTANDING THE ROLE OF NATURAL A-SPECIFIC B CELL RESPONSES IN AD PROGRESSION | 202421229349300027 |
| 2023 | Icahn Scool of Medicine at Mount Sinai New York, NY | A | $172,500 | paid | INVESTIGATING BONE MARROW HEMATOPOIESIS AND THE LINK BETWEEN SLEEP FRAGMENTATION AND VASCULAR INFLAMMATION IN AD | 202421229349300027 |
| 2023 | Massachusetts General Hospital Boston, MA | A | $172,500 | paid | TAU AND -AMYLOID ARE INNATE IMMUNE ANTIMICROBIAL PEPTIDES IN THE BRAIN | 202421229349300027 |
| 2023 | The Salk Institute for Biologial Studies La Jolla, CA | A | $172,500 | paid | THE ROLE OF ASTROCYTE-SECRETED IGFBP2 IN THE PROGRESSION OF ALZHEIMER'S DISEASE | 202421229349300027 |
| 2023 | Icahn Scool of Medicine at Mount Sinai New York, NY | A | $172,500 | paid | STRESS AND NEUROVASCULAR-IMMUNE NETWORKS IN ALZHEIMER'S DISEASE | 202421229349300027 |
| 2023 | Northwestern University Chicago, IL | A | $172,500 | paid | T CELL EPIGENETICS IN ALZHEIMER'S DISEASE | 202421229349300027 |
| 2023 | Icahn Scool of Medicine at Mount Sinai New York, NY | A | $172,500 | paid | IN VIVO MODELS FOR GOLGI FRAGMENTATION AND THE MOLECULAR PATHOGENESIS OF ALZHEIMER'S DISEASE | 202421229349300027 |
| 2023 | Mayo Clinic Jacksonville Jacksonville, FL | A | $172,500 | paid | TARGETING MICROGLIAL TSG 101 FOR SYNAPTIC PROTECTION AND COGNITIVE ENHANCEMENT IN ALZHEIMER'S DISEASE | 202421229349300027 |
| 2023 | Massachusetts General Hospital Boston, MA | A | $172,000 | paid | REGIONAL VARIABILITY OF PATHOLOGY-ASSOCIATED PROPERTIES OF TAU IN POSTERIOR CORTICAL ATROPHY | 202421229349300027 |
| 2023 | Harvard Medical School Cambridge, MA | A | $150,000 | paid | PRECISION MEDICINE PREDICTION MODEL FOR ALZHEIMER'S DISEASE USING COOPERATIVE LEARNING APPROACHES FOR MULTI-OMIC DATA | 202421229349300027 |
| 2023 | Northwestern University Chicago, IL | A | $136,827 | paid | INTERROGATING LEVETIRACETAM'S IMPACT ON AMYLOID PATHOLOGY AND PRESYNAPTIC PROTEOSTASIS IN KNOCK-IN MOUSE MODELS WITH HUMANIZED ABETA | 202421229349300027 |
| 2023 | Massachusetts General Hospital Boston, MA | A | $125,000 | paid | THE IMPACT OF MUTATIONS IN THE LIGAND-BINDING DOMAIN OF CD33 ON ALZHEIMER'S DISEASE PATHOGENESIS | 202421229349300027 |
| 2023 | Beth Israel Deaconess Medical Center Boston, MA | A | $118,450 | paid | AGP: GENOMIC VARIANT CALLING AND DATA MANAGEMENT FOR THE CURE ALZHEIMER'S FUND ALZHEIMER'S GENOME PROJECT | 202421229349300027 |
| 2023 | Washington University St Louis, MO | A | $113,655 | paid | CHARACTERIZATION OF MOLECULAR BIOMARKER PROFILES THROUGHOUT THE PATHOBIOLOGICAL CONTINUUM | 202421229349300027 |
| 2023 | Massachusetts General Hospital Boston, MA | A | $95,594 | paid | GENERAL SCIENTIFIC SUPPORT | 202421229349300027 |
| 2023 | University of Michigan Ann Arbor, MI | A | $57,500 | paid | IN VIVO MODELS FOR GOLGI FRAGMENTATION AND THE MOLECULAR PATHOGENESIS OF ALZHEIMER'S DISEASE | 202421229349300027 |
| 2023 | Harvard Medical School Boston, MA | A | $40,250 | paid | GENETIC ANCESTRY-SPECIFIC RISK ESTIMATION OF ALZHEIMER'S DISEASE (AD) IN THE APOE REGION | 202421229349300027 |
| 2022 | Massachusetts General Hospital Charlestown, MA | A | $1,955,000 | paid | THECUREALZALZHEIMERS GENOME PROJECT | 202331259349301933 |
| 2022 | Washington University St Louis, MO | A | $345,000 | paid | APOE CONSORTIUM: ROLE OF APOE ISOFORMS IN IMMUNE RESPONSES IN A MODEL OF TAUOPATHY | 202331259349301933 |
| 2022 | Washington University St Louis, MO | A | $345,000 | paid | BEE: CROSSTALK OF CNS BARRIERS AND CLEARANCE ROUTES IN HOMEOSTASIS AND ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Whitehead Cambridge, MA | A | $307,500 | paid | CIRCUITS: IMPACT OF EPIGENETIC AND CELLULAR VARIANTS ON ALZHEIMERS DISEASE PATHOLOGY | 202331259349301933 |
| 2022 | Boston Children's Hospital Boston, MA | A | $300,000 | paid | NIC: UNDERSTANDING THE CONSEQUENCES OF NON-CODING AD RISK ALLELES ON MICROGLIA FUNCTION | 202331259349301933 |
| 2022 | University of California San Diego La Jolla, CA | A | $287,500 | paid | BEE: IDENTIFYING THE BLOOD-BRAIN BARRIER CHANGES DURING ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Massachusetts General Hospital Charlestown, MA | A | $287,500 | paid | NIC: BIOMARKER TOOL DEVELOPMENT IN CAF NEUROIMMUNE CONSORTIUM | 202331259349301933 |
| 2022 | Brigham and Women's Boston, MA | A | $287,500 | paid | APOE CONSORTIUM: APOE4-MEDIATED DYSFUNCTION OF CD8 T CELL-MICROGLIA CROSSTALK IN ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Weill Cornell New York, NY | A | $287,500 | paid | BEE: BIOCHEMICAL AND FUNCTIONAL ANALYSIS OF CSF AND LYMPH FOLLOWING CHANGES IN BRAIN FLUID DYNAMICS | 202331259349301933 |
| 2022 | University of Texas Southwestern Medical Center Dallas, TX | A | $287,000 | paid | ADTC: THE ROLE OF VCP/P97 IN TAU PRION REPLICATION | 202331259349301933 |
| 2022 | Massachusetts General Hospital Charlestown, MA | A | $286,595 | paid | ADTC: HOW DO SOLUBLE TAU SPECIES REPLICATE? | 202331259349301933 |
| 2022 | Northwestern Chicago, IL | A | $286,357 | paid | ADTC: THE ROLE OF A-INDUCED MEMBRANE DAMAGE IN TAU PATHOLOGY | 202331259349301933 |
| 2022 | Washington University St Louis, MO | A | $252,077 | paid | APOE: ASSESSING THE ADDED DIAGNOSTIC VALUE OF PERIPHERAL APOE PROTEIN LEVELS IN CURRENT BLOOD-BASED BIOMARKER ASSAYS FOR CNS AMYLOIDOSIS | 202331259349301933 |
| 2022 | University of California Irvine Irvine, CA | A | $250,000 | paid | NIC: EXAMINING THE ROLE OF HUMAN MICROGLIA IN THE TRANSITION BETWEEN PARENCHYMAL AND VASCULAR BETA-AMYLOID PATHOLOGY | 202331259349301933 |
| 2022 | Massachusetts General Hospital Charlestown, MA | A | $250,000 | paid | CREATION OF A FIBROBLAST/IPS CELL BANK TO FACILITATE PERIPHERAL/BRAIN COMPARISONS, AND ALLOW MOLECULAR INVESTIGATIONS INTO MOLECULAR MECHANISMS UNDERLYING DIFFERENCES IN DISEASE AGGRESSIVENESS | 202331259349301933 |
| 2022 | University of California San Diego La Jolla, CA | A | $250,000 | paid | NIC: LEVERAGING ENHANCER LANDSCAPES TO DECODE AD RISK ALLELES IN MICROGLIA | 202331259349301933 |
| 2022 | Weill Cornell New York, NY | A | $250,000 | paid | DEVELOPMENT OF HUMAN CGAS INHIBITORS TO TREAT ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Harvard Medical School Boston, MA | A | $250,000 | paid | NIC: ASSESSING THE LINKS BETWEEN THE MS4A RISK GENES, MICROGLIA, AND ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Beth Israel Deaconess Medical Center Boston, MA | A | $248,980 | paid | CIRCUITS: AUNIFIED APPROACH TO ACTIONABLE ALZHEIMERS DISEASE SIGNATURES | 202331259349301933 |
| 2022 | Northwestern Chicago, IL | A | $246,804 | paid | SINGLE NUCLEUS RNA SEQUENCING ANALYSIS OF ACE1 R1284Q KNOCKIN MICE | 202331259349301933 |
| 2022 | University of Michigan Ann Arbor, MI | A | $243,407 | paid | NEUROBIOLOGICAL BASIS OF COGNITIVE IMPAIRMENT IN AFRICAN AMERICANS: DEEP PHENOTYPING OF OLDER AFRICAN AMERICANS AT RISK OF DEMENTIA | 202331259349301933 |
| 2022 | Massachusetts General Hospital Charlestown, MA | A | $230,590 | paid | AD4: HIGH-THROUGHPUT DRUG SCREENING FOR ALZHEIMER'S DISEASE USING 3D HUMAN NEURAL CULTURE SYSTEMS | 202331259349301933 |
| 2022 | University of Connecticut Farmington, CT | A | $230,000 | paid | AD PATHOPHYSIOLOGY ALTERS THE LEVEL OF ELECTRICAL AND CHEMICAL SYNAPSE COUPLING IN THE NETWORK OF GABAERGIC PV+ INTERNEURONS EARLY IN DISEASE COURSE | 202331259349301933 |
| 2022 | University of Texas Southwestern Medical Center Dallas, TX | A | $230,000 | paid | RNA AND TAU SEED FORMATION | 202331259349301933 |
| 2022 | University of Chicago Chicago, IL | A | $229,033 | paid | TEMPORAL RELATIONSHIPS BETWEEN GUT DYSBIOSIS AND MICROGLIA CELL ACTIVATION FOLLOWING ANTIBIOTIC TREATMENT | 202331259349301933 |
| 2022 | Houston Methodist Houston, TX | A | $225,000 | paid | AD4: UNCOVERING THE MOLECULAR MECHANISM OF SELECTED DRUG CANDIDATES DERIVED FROM SYSTEMATICS ALZHEIMERS DRUG REPOSITIONING | 202331259349301933 |
| 2022 | University of Southern California Los Angeles, CA | A | $219,535 | paid | AIR POLLUTION AND AD RISK INTERACT WITH PREMATURE AGING OF NEURAL STEM CELLS AND APOE ALLELES | 202331259349301933 |
| 2022 | Mount Sinai New York, NY | A | $217,327 | paid | MICROGLIAL-SPECIFIC INPP5D KNOCKDOWN MODULATES BEHAVIOR, AMYLOIDOSIS, AND TAUOPATHY IN ALZHEIMER'S MOUSE MODELS | 202331259349301933 |
| 2022 | University of Chicago Chicago, IL | A | $210,871 | paid | IDENTIFYING THE SEX-SPECIFIC ROLES OF THE GUT-MICROBIOME-BRAIN AXIS IN A MOUSE MODEL OF AB AMYLOIDOSIS | 202331259349301933 |
| 2022 | Yale New Haven, CT | A | $204,238 | paid | BEE: CNS FLUID HOMEOSTASIS AND WASTE CLEARANCE IN ALZHEIMERS DISEASE CHARACTERIZED BY MRI | 202331259349301933 |
| 2022 | Johns Hopkins Baltimore, MD | A | $201,250 | paid | HUMAN BRAIN CD33 LIGAND, RPTPS3L, LIMITS MICROGLIAL PHAGOCYTOSIS AND CONTRIBUTES TO ALZHEIMERS DISEASE PROGRESSION | 202331259349301933 |
| 2022 | University of Southern California Los Angeles, CA | A | $201,250 | paid | PRENATAL INFLAMMATION EFFECTS ON BLOOD BRAIN BARRIER FUNCTION AND AD-RELATED PATHOLOGIES ACROSS THE LIFESPAN | 202331259349301933 |
| 2022 | University of Virginia Charlottesville, VA | A | $201,250 | paid | EXPLORING THE THERAPEUTIC POTENTIAL OF CLUSTERIN IN A PRECLINICAL MODEL OF ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Brigham and Women's Boston, MA | A | $201,250 | paid | NEUROIMMUNE CONNECTOME PERTURBATIONS IN ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Brigham and Women's Boston, MA | A | $201,250 | paid | TARGETING THE MICROBIOME AND INNATE IMMUNITY IN ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | University of California San Francisco San Francisco, CA | A | $201,250 | paid | UNDERSTANDING HOW HUMAN BRAIN VASCULAR CELLS MEDIATE GENETIC RISK FOR ALZHEIMER'S DISEASE | 202331259349301933 |
| 2022 | Mayo Jacksonville Jacksonville, FL | A | $201,250 | paid | ABCA7 LOSS OF FUNCTION IN AGING AND ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Harvard Medical School Boston, MA | A | $201,250 | paid | DISSECTING THE MODULATORY ROLES OF INTERLEUKIN-17 RECEPTOR D IN ALZHEIMER'S DISEASE | 202331259349301933 |
| 2022 | University of California San Francisco San Francisco, CA | A | $201,250 | paid | ROLE OF THE CIRCULATING EXERKINE GPLD1 IN AMELIORATING ALZHEIMERS DISEASE PATHOLOGY | 202331259349301933 |
| 2022 | Mayo Jacksonville Jacksonville, FL | A | $201,250 | paid | EVALUATING TMEM106B ACCUMULATION IN AD | 202331259349301933 |
| 2022 | Massachusetts General Hospital Charlestown, MA | A | $200,417 | paid | CIRCADIAN PERTURBATIONS OF THE VASCULOME AND MICROGLIOME IN ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Carnegie Mellon Pittsburgh, PA | A | $200,000 | paid | CIRCUITS: INTERPRETING ALZHEIMERS DISEASE-ASSOCIATED GENETIC VARIATION AT ENHANCER REGIONS | 202331259349301933 |
| 2022 | Duke Durham, NC | A | $199,162 | paid | SEX DIFFERENCES IN ALZHEIMER'S DISEASE PROGRESSION: FRAMINGHAM HEART STUDY | 202331259349301933 |
| 2022 | University of Virginia Charlottesville, VA | A | $198,932 | paid | TOXIC EFFECTS OF EXTRACELLULAR TAU OLIGOMERS ON NEURONS | 202331259349301933 |
| 2022 | Massachusetts General Hospital Charlestown, MA | A | $197,500 | paid | AD4: MODULATING CD33 FUNCTION AND NEUROINFLAMMATION AS A THERAPEUTIC APPROACH FOR ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Boston University Boston, MA | A | $197,500 | paid | AD4: BLOCKING SYNAPTOTOXICITY IN ALZHEIMER'S 3D MODELS | 202331259349301933 |
| 2022 | Duke Durham, NC | A | $194,253 | paid | CONTRIBUTIONS OF IL34 SIGNALING TO MICROGLIAL FUNCTION AND ALZHEIMERS PATHOLOGY IN MICE | 202331259349301933 |
| 2022 | Brigham and Women's Boston, MA | A | $183,562 | paid | IMMUNOTHERAPIES TARGETING THE MICROBIOTA TO PREVENT COGNITIVE DECLINE IN ALZHEIMER'S DISEASE | 202331259349301933 |
| 2022 | Massachusetts General Hospital Charlestown, MA | A | $177,675 | paid | G2T, AD4 AND GENERAL SCIENTIFIC SUPPORT | 202331259349301933 |
| 2022 | New York University New York, NY | A | $174,883 | paid | THE ROLE OF ASTROCYTE-DERIVED TOXIC LIPIDS MEDIATING DEGENERATION IN ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | University of Virginia Charlottesville, VA | A | $172,500 | paid | TARGETING A MASTER INNATE IMMUNE ADAPTOR MOLECULE IN ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Mount Sinai New York, NY | A | $172,500 | paid | STRESS AND NEUROVASCULAR-IMMUNE NETWORKS IN ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Washington University St Louis, MO | A | $172,500 | paid | TARGETING REACTIVE ASTROCYTES FOR THERAPEUTIC INTERVENTION OF ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Weill Cornell New York, NY | A | $172,500 | paid | IDENTIFICATION OF CD33 ANTAGONISTS | 202331259349301933 |
| 2022 | Mayo Jacksonville Jacksonville, FL | A | $172,500 | paid | HARNESSING MENINGEAL LYMPHATICS AND IMMUNITY TO ALLEVIATE APOE4-INDUCED BRAIN DYSFUNCTION | 202331259349301933 |
| 2022 | Stanford Stanford, CA | A | $172,500 | paid | A TRANSCRIPTIONAL REJUVENATION SIGNATURE FOR ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Washington University St Louis, MO | A | $172,500 | paid | NEURONAL SUBTYPE-SPECIFIC MODELING OF ALZHEIMERS DISEASE BY DIRECT NEURONAL REPROGRAMMING OF PATIENT FIBROBLASTS | 202331259349301933 |
| 2022 | Massachusetts General Hospital Charlestown, MA | A | $172,500 | paid | EFFECTS OF DE-PALMITOYLATION AND ACAT INHIBITION ON AXONAL AB GENERATION VIA MAM-ASSOCIATED PALAPP | 202331259349301933 |
| 2022 | Tufts Boston, MA | A | $172,500 | paid | IN VIVO CHARACTERIZATION OF A LOSS OF FUNCTION GGA3 RARE VARIANT ASSOCIATED WITH AD | 202331259349301933 |
| 2022 | Mount Sinai New York, NY | A | $172,500 | paid | SYSTEMS INTEGRATION AND THERAPEUTICS TRANSLATION IN ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Rockefeller New York, NY | A | $172,500 | paid | STIMULATING SYNAPTIC PROTEASOME ACTIVITY FOR THE TREATMENT OF ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Unc-Chapel Hill Chapel Hill, NC | A | $172,500 | paid | SMALL MOLECULE ACTIVATORS OF PLC-Y2 AS NOVEL THERAPEUTICS FOR ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Yale New Haven, CT | A | $172,500 | paid | ROLE OF MICROGLIAL MATRICELLULAR PROTEIN SPARC IN CONTROL OF INFLAMMASOME ACTIVATION | 202331259349301933 |
| 2022 | Weill Cornell New York, NY | A | $172,500 | paid | GUT MICROBIOTA, ENDOTHELIAL DYSFUNCTION AND TAU-MEDIATED COGNITIVE IMPAIRMENT | 202331259349301933 |
| 2022 | Mount Sinai New York, NY | A | $172,500 | paid | ESTABLISHING THE MOLECULAR AND CELLULAR MECHANISMS AND BIOMARKERS OF APOE4-MEDIATED SUSCEPTIBILITY TO TAU-RELATED COGNITIVE IMPAIRMENTS | 202331259349301933 |
| 2022 | Mskcc New York, NY | A | $172,500 | paid | THE ROLE OF IFITM3 AND GAMMA SECRETASE IN MICROGLIA | 202331259349301933 |
| 2022 | Wake Forest Winstonsalem, NC | A | $172,500 | paid | INVESTIGATING THE ROLE OF TAU PROTEIN IN NEURONAL SENESCENCE INDUCTION AND MAINTENANCE | 202331259349301933 |
| 2022 | Massachusetts General Hospital Charlestown, MA | A | $172,500 | paid | DEVELOPMENT OF A MULTICELLULAR BRAIN MODEL TO STUDY BRAIN-VASCULAR-PERIPHERAL IMMUNE CELLS CROSSTALK INALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Massachusetts General Hospital Charlestown, MA | A | $172,500 | paid | NEUROPROTECTIVE EFFECTS OF THE EXERCISE HORMONE IRISIN IN ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Brigham and Women's Boston, MA | A | $172,500 | paid | ROLE OF CHECKPOINT MOLECULE TIM-3 IN MICROGLIA REGULATION IN ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Massachusetts General Hospital Charlestown, MA | A | $172,500 | paid | NEUROPROTECTIVE EFFECTS OF THE EXERCISE HORMONE IRISIN IN ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Massachusetts General Hospital Charlestown, MA | A | $172,500 | paid | REGIONAL VARIABILITY OF PATHOLOGY-ASSOCIATED PROPERTIES OF TAU IN POSTERIOR CORTICAL ATROPHY | 202331259349301933 |
| 2022 | University of California San Diego La Jolla, CA | A | $172,500 | paid | FUNCTIONAL BASIS FOR NOVEL PKC K56R MUTATION IN ALZHEIMER'S DISEASE | 202331259349301933 |
| 2022 | Weill Cornell New York, NY | A | $172,500 | paid | ROLE OF MICROGLIA IN DEGRADATION AND TRIMMING OF ALZHEIMERS AMYLOID BETA | 202331259349301933 |
| 2022 | Washington University St Louis, MO | A | $172,500 | paid | CONTRIBUTION OF SKULL BONE MARROW-DERIVED CELLS TO ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Broad Institute Cambridge, MA | A | $171,207 | paid | REVEALING NEW GENES AND PATHWAYS AT THE INTERSECTION OF LIPOTOXIC AND GENETIC RISK FOR ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Barrow Phoenix, AZ | A | $170,877 | paid | HARNESSING BIG DATA TO UNDERSTAND ALZHEIMER'S DISEASE RISK | 202331259349301933 |
| 2022 | Boston University Boston, MA | A | $167,707 | paid | APOE CONSORTIUM: MODULATION OF SELECTIVE NEURONAL VULNERABILITY IN ALZHEIMERS DISEASE BY APOE | 202331259349301933 |
| 2022 | Baylor College of Medicine Houston, TX | A | $167,637 | paid | ELUCIDATING THE ROLE OF SOLUBLE EPOXIDE HYDROLASE AND ARACHIDONIC ACID METABOLISM IN NEUROINFLAMMATION AND ALZHEIMERS DISEASE | 202331259349301933 |
| 2022 | Boston Children's Hospital Boston, MA | A | $149,500 | paid | NEUROINFLAMMATION CONTRIBUTIONS TO ALZHEIMERS DISEASE: ROLE OF THE CHOROID PLEXUS | 202331259349301933 |
| 2022 | Washington University Saint Louis, MO | A | $120,015 | paid | CHARACTERIZATION OF MOLECULAR BIOMARKER PROFILES THROUGHOUT THE PATHOBIOLOGICAL CONTINUUM | 202331259349301933 |
| 2022 | New York University New York, NY | A | $115,000 | paid | NIC: INVESTIGATION OF AD RISK ALLELES IN ASTROCYTES FOCUS ON CHOLESTEROL TRANSPORT AND MICROGLIA INTERACTIONS | 202331259349301933 |
| 2022 | Salk La Jolla, CA | A | $115,000 | paid | CIRCUITS: IMPACT OF EPIGENETIC AND CELLULAR VARIANTS ON ALZHEIMERS DISEASE PATHOLOGY | 202331259349301933 |
| 2022 | Albert Einstein College of Medicine Bronx, NY | A | $100,000 | paid | APPLICATION OF MACHINE LEARNING METHODS IN ALZHEIMERS DISEASE CLINICAL TRIALS | 202331259349301933 |
| 2022 | Stony Brook Stony Brook, NY | A | $82,166 | paid | BEE: CNS FLUID HOMEOSTASIS AND WASTE CLEARANCE IN ALZHEIMERS DISEASE CHARACTERIZED BY MRI | 202331259349301933 |
| 2021 | Massachusetts General Hospital Boston, MA | A | $1,495,000 | paid | THE CURE ALZ ALZHEIMER'S GENOME PROJECT | 202241309349304019 |
| 2021 | The Broad Institute Inc Cambridge, MA | A | $550,000 | paid | CIRCUITS: CONSORTIUM TO INFER REGULATORY CIRCUITS AND UNCOVER INNOVATIVE THERAPEUTIC STRATEGIES PRODUCTION GROUP | 202241309349304019 |
| 2021 | Whitehead Institute for Biomedical Research Cambridge, MA | A | $307,500 | paid | CIRCUITS: IMPACT OF GENETIC, EPIGENETIC AND CELLULAR VARIANTS ON ALZHEIMER'S DISEASE PATHOLOGY | 202241309349304019 |
| 2021 | Massachusetts General Hospital Boston, MA | A | $300,000 | paid | UNDERSTANDING HUMAN BRAIN RESILIENCE TO ALZHEIMER'S PATHOLOGY | 202241309349304019 |
| 2021 | Washington University St Louis St Louis, MO | A | $300,000 | paid | APOE CONSORTIUM: UNDERSTANDING THE EFFECT OF APOE ON TAU-MEDIATED NEURODEGENERATION | 202241309349304019 |
| 2021 | The University of California San Diego La Jolla, CA | A | $291,374 | paid | CONTINUING STUDIES OF THE EFFECTS OF GSM 776890 ADMINISTRATION ON AMYLOID SPECIES AND MICROGLIOSIS IN OLDER ALZHEIMER'S MODEL MICE | 202241309349304019 |
| 2021 | University of Southern California Los Angeles, CA | A | $257,679 | paid | AIR POLLUTION AND AD RISK INTERACT WITH PREMATURE AGING OF NEURAL STEM CELLS AND APOE ALLELES | 202241309349304019 |
| 2021 | Washington University St Louis St Louis, MO | A | $250,000 | paid | BRAIN ENTRY & EXIT CONSORTIUM: CROSSTALK OF CNS BARRIERS AND CLEARANCE ROUTES IN HOMEOSTASIS AND ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | Mayo Clinic Rochester, MN | A | $250,000 | paid | APOE CONSORTIUM: COUNTERACTING PATHOGENIC EVENTS IN AD WITH PERIPHERAL OR CENTRAL APOE | 202241309349304019 |
| 2021 | Massachusetts General Hospital Boston, MA | A | $250,000 | paid | CHARACTERIZING GUT MICROBIOME SYNERGY WITH EMPHASIS ON MYCOBIOME AND ITS IMPACT ON ALZHEIMER'S DISEASE (AD) PATHOLOGY IN AD MOUSE MODELS | 202241309349304019 |
| 2021 | Brigham and Women's Hospital Boston, MA | A | $250,000 | paid | APOE CONSORTIUM: THE ROLE OF APOE IN MICROGLIA REGULATION IN NEURODEGENERATION | 202241309349304019 |
| 2021 | Weill Medical College of Cornell University New York, NY | A | $250,000 | paid | DEVELOPMENT OF HUMAN CGAS INHIBITORS TO TREAT ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | The Trustees of Boston University Boston, MA | A | $250,000 | paid | APOE CONSORTIUM: REGULATION BY APOE OF SELECTIVE NEURONAL VULNERABILITY TO ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | University of Texas Southwestern Medical Center Dallas, TX | A | $250,000 | paid | MECHANISMS OF TAU PROPAGATION ACROSS THE PLASMA MEMBRANE | 202241309349304019 |
| 2021 | New York University School of Medicine New York, NY | A | $250,000 | paid | NEUROINFLAMMATION CONSORTIUM: INVESTIGATION OF AD RISK ALLELES IN ASTROCYTES FOCUS ON CHOLESTEROL TRANSPORT AND MICROGLIA INTERACTION | 202241309349304019 |
| 2021 | University of Southern California Los Angeles, CA | A | $250,000 | paid | CELLULAR AND MOLECULAR STUDIES OF APOE REGULATION OF BLOOD-BRAIN BARRIER, SYNAPTIC AND NEURONAL FUNCTIONS AND PROTECTION STRATEGIES IN MOUSE MODELS WITH AND WITHOUT ALZHEIMER'S PATHOLOGY | 202241309349304019 |
| 2021 | Beth Israel Deaconess Medical Center Boston, MA | A | $249,026 | paid | CIRCUITS: A UNIFIED APPROACH TO ACTIONABLE ALZHEIMER'S DISEASE SIGNATURES | 202241309349304019 |
| 2021 | Harvard College Boston, MA | A | $244,496 | paid | ANALYTICAL AND STATISTICAL TOOLS FOR SEQUENCE ANALYSIS FOR ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | University of Virginia Charlottesville, VA | A | $229,249 | paid | ADULT HUMAN INEURONS: A NEXT GENERATION DRUG SCREENING PLATFORM FOR ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | Houston Methodist Hospital Foundation Houston, TX | A | $200,000 | paid | 3DDS CONSORTIUM: UNCOVERING THE MOLECULAR MECHANISMS OF SELECTED DRUG CANDIDATES DERIVED FROM SYSTEMATIC ALZHEIMER'S DRUG REPOSITIONING | 202241309349304019 |
| 2021 | Carnegie Mellon University Pittsburgh, PA | A | $200,000 | paid | CIRCUITS: INTERPRETING ALZHEIMER'S DISEASEASSOCIATED GENETIC VARIATION AT ENHANCER REGIONS | 202241309349304019 |
| 2021 | University of Southern California Los Angeles, CA | A | $191,008 | paid | PROTECTION AGAINST APOE4 WITH LONGEVITY-PROMOTING INTERVENTIONS | 202241309349304019 |
| 2021 | Brigham and Women's Hospital Boston, MA | A | $178,612 | paid | IMMUNOTHERAPIES TARGETING THE MICROBIOTA TO PREVENT COGNITIVE DECLINE IN ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | New York University School of Medicine New York, NY | A | $174,754 | paid | THE ROLE OF ASTROCYTE-DERIVED TOXIC LIPIDS MEDIATING DEGENERATION IN AD | 202241309349304019 |
| 2021 | Mayo Clinic Rochester, MN | A | $172,500 | paid | HARNESSING MENINGEAL LYMPHATICS AND IMMUNITY TO ALLEVIATE APOE4-INDUCED BRAIN DYSFUNCTION | 202241309349304019 |
| 2021 | The University of California San Diego La Jolla, CA | A | $172,500 | paid | BRAIN ENTRY & EXIT CONSORTIUM: IDENTIFYING THE BLOOD-BRAIN BARRIER CHANGES DURING ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | Massachusetts General Hospital Boston, MA | A | $172,500 | paid | EFFECTS OF DE-PALMITOYLATION AND ACAT INHIBITION ON AXONAL AB GENERATION VIA MAM-ASSOCIATED PALAPP | 202241309349304019 |
| 2021 | The University of California San Diego La Jolla, CA | A | $172,500 | paid | FUNCTIONAL BASIS FOR NOVEL PKC, K56R MUTATION IN ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | Massachusetts General Hospital Boston, MA | A | $172,500 | paid | ALZHEIMER'S DISEASE DRUG DISCOVERY AND DEVELOPMENT CONSORTIUM: MODULATING CD33 FUNCTION AND NEUROINFLAMMATION AS A THERAPEUTIC APPROACH FOR ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | Massachusetts General Hospital Boston, MA | A | $172,500 | paid | NEUROPROTECTIVE EFFECTS OF THE EXERCISE HORMONE IRISIN IN ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | Washington University St Louis St Louis, MO | A | $172,500 | paid | CONTRIBUTION OF SKULL BONE MARROW-DERIVED CELLS TO ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | Massachusetts General Hospital Boston, MA | A | $172,500 | paid | DEVELOPMENT OF A MULTICELLULAR BRAIN MODEL TO STUDY BRAIN-VASCULAR-PERIPHERAL IMMUNE CELLS CROSSTALK IN ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | Washington University St Louis St Louis, MO | A | $172,500 | paid | UNDERSTANDING THE ROLE OF NATURAL AB-SPECIFIC B CELL RESPONSES IN AD PROGRESSION | 202241309349304019 |
| 2021 | Icahn School of Medicine at Mount Sinai New York, NY | A | $172,500 | paid | ESTABLISHING THE MOLECULAR AND CELLULAR MECHANISMS AND BIOMARKERS OF APOE4-MEDIATED SUSCEPTIBILITY TO TAU-RELATED COGNITIVE IMPAIRMENTS | 202241309349304019 |
| 2021 | Memorial Sloan Kettering Cancer New York, NY | A | $172,500 | paid | THE ROLE OF IFITM3 AND GAMMA SECRETASE IN MICROGLIA | 202241309349304019 |
| 2021 | Massachusetts General Hospital Boston, MA | A | $172,500 | paid | TAU AND B-AMYLOID ARE INNATE IMMUNE ANTIMICROBIAL | 202241309349304019 |
| 2021 | Washington University St Louis St Louis, MO | A | $172,500 | paid | NEURONAL SUBTYPE-SPECIFIC MODELING OF ALZHEIMER'S DISEASE BY DIRECT NEURONAL REPROGRAMMING OF PATIENT FIBROBLASTS | 202241309349304019 |
| 2021 | Mayo Clinic Rochester, MN | A | $172,500 | paid | THE ROLE OF CLUSTERIN IN TAU PATHOLOGY | 202241309349304019 |
| 2021 | The Trustees of Boston University Boston, MA | A | $172,500 | paid | ALZHEIMER'S DISEASE DRUG DISCOVERY AND DEVELOPMENT CONSORTIUM: BLOCKING SYNAPTOTOXICITY IN ALZHEIMER'S 3D MODELS | 202241309349304019 |
| 2021 | The University of California San Diego La Jolla, CA | A | $172,500 | paid | THE NEDD4-1 AND PKCA CONNECTION IN ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | Mayo Clinic Jacksonville Jacksonville, FL | A | $172,500 | paid | ABCA7 LOSS OF FUNCTION IN AGING AND ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | Brigham and Women's Hospital Boston, MA | A | $172,500 | paid | ROLE OF CHECKPOINT MOLECULE TIM-3 IN REGULATING MICROGLIA IN ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | The Salk Institute for Biological Studies La Jolla, CA | A | $172,500 | paid | THE ROLE OF ASTROCYTE-SECRETED IGFBP2 IN THE PROGRESSION OF ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | The Rockefeller University New York, NY | A | $172,500 | paid | APOE CONSORTIUM: REGULATION BY APOE OF SELECTIVE NEURONAL VULNERABILITY TO ALZHEIMER'S DISEASE (YEAR 3) | 202241309349304019 |
| 2021 | University of Southern California Los Angeles, CA | A | $172,500 | paid | AIR POLLUTION AND AD RISK INTERACT WITH PREMATURE AGING OF NEURAL STEM CELLS AND APOE ALLELES | 202241309349304019 |
| 2021 | Yale University New Haven, CT | A | $172,500 | paid | THE NEUROPROTECTIVE GLIAL BARRIER: A MULTICELLULAR REACTION WITH THERAPEUTIC POTENTIAL IN AD | 202241309349304019 |
| 2021 | Mayo Clinic Rochester, MN | A | $172,500 | paid | PATIENT-BASED STRUCTURAL AND FUNCTIONAL BIOLOGY OF TAUOPATHIES (YEAR 2) | 202241309349304019 |
| 2021 | Massachusetts General Hospital Boston, MA | A | $172,500 | paid | ALZHEIMER'S DISEASE DRUG DISCOVERY AND DEVELOPMENT CONSORTIUM: HIGH-THROUGHPUT DRUG SCREENING FOR ALZHEIMER'S DISEASE USING 3D HUMANNEURAL CULTURE SYSTEMS YR 1 OF 2 | 202241309349304019 |
| 2021 | Massachusetts General Hospital Boston, MA | A | $172,500 | paid | NEUROPROTECTIVE EFFECTS OF THE EXERCISE HORMONE IRISIN IN ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | University of Virginia Charlottesville, VA | A | $172,500 | paid | TARGETING A MASTER INNATE IMMUNE ADAPTOR MOLECULE IN ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | Brigham and Women's Hospital Boston, MA | A | $172,500 | paid | THE ROLE OF MGND-NEURODEGENERATIVE CLEC7A+ MICROGLIA IN AN AD MOUSE MODEL | 202241309349304019 |
| 2021 | Icahn School of Medicine at Mount Sinai New York, NY | A | $172,500 | paid | SYSTEMS INTEGRATION AND THERAPEUTICS TRANSLATION. | 202241309349304019 |
| 2021 | Weill Medical College of Cornell University New York, NY | A | $172,500 | paid | BRAIN ENTRY AND EXIT CONSORTIUM: LYMPHATICS AND CNS FLUID HOMEOSTASIS | 202241309349304019 |
| 2021 | Mayo Clinic Jacksonville Jacksonville, FL | A | $172,500 | paid | TARGETING MICROGLIAL TSG 101 FOR SYNAPTIC PROTECTION AND COGNITIVE ENHANCEMENT IN ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | Icahn School of Medicine at Mount Sinai New York, NY | A | $172,500 | paid | INVESTIGATING BONE MARROW HEMATOPOIESIS AS THE LINK BETWEEN SLEEP FRAGMENTATION AND VASCULAR INFLAMMATION IN AD | 202241309349304019 |
| 2021 | Weill Medical College of Cornell University New York, NY | A | $172,500 | paid | ROLE OF MICROGLIA IN DEGRADATION AND TRIMMING OF ALZHEIMER'S AMYLOID BETA | 202241309349304019 |
| 2021 | Brigham and Women's Hospital Boston, MA | A | $172,500 | paid | TARGETING THE MICROBIOME AND INNATE IMMUNITY | 202241309349304019 |
| 2021 | Massachusetts General Hospital Boston, MA | A | $172,500 | paid | G2T, AD4, ACTFAST AND GENERAL SCIENTIFIC SUPPORT | 202241309349304019 |
| 2021 | Northwestern University Evanston, IL | A | $172,500 | paid | T CELL EPIGENETICS IN ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | Unversity of Kentucky Lexington, KY | A | $172,500 | paid | APOLIPOPROTEIN E AND IMMUNOMETABOLISM IN ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | The Broad Institute Inc Cambridge, MA | A | $172,500 | paid | REVEALING NEW GENES AND PATHWAYS AT THE INTERSECTION OF LIPOTOXIC AND GENETIC RISK FOR ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | Massachusetts General Hospital Boston, MA | A | $170,907 | paid | EFFECTS OF CEREBROVASCULAR INSUFFICIENCY AND EXERCISE ON THE AD BRAIN VASCULOMA | 202241309349304019 |
| 2021 | The Baylor College of Medicine Houston, TX | A | $167,920 | paid | ELUCIDATING THE ROLE OF SOLUBLE EPOXIDE HYDROLASE AND ARACHIDONIC ACID METABOLISM IN NEUROINFLAMMATION AND ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | Northwestern University Evanston, IL | A | $164,314 | paid | INTERROGATING LEVETIRACETAM'S IMPACT ON AMYLOID PATHOLOGY AND PRESYNAPTIC PROTEOSTASIS IN KNOCK-IN MOUSE MODELS WITH HUMANIZED ABETA | 202241309349304019 |
| 2021 | Boston Childrens Hospital Boston, MA | A | $138,000 | paid | NEUROINFLAMMATION CONTRIBUTIONS TO ALZHEIMER'S DISEASE: ROLE OF THE CHOROID PLEXUS | 202241309349304019 |
| 2021 | Massachusetts General Hospital Boston, MA | A | $115,000 | paid | (YR 2) BRAIN ENTRY & EXIT CONSORTIUM: HUMAN 3D NEUROVASCULAR INTERACTION AND MENINGEAL LYMPHATICS MODELS WITH APPLICATION TO ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | The Salk Institute for Biological Studies La Jolla, CA | A | $115,000 | paid | CIRCUITS: IMPACT OF EPIGENETIC AND CELLULAR VARIANTS ON ALZHEIMER'S DISEASE PATHOLOGY | 202241309349304019 |
| 2021 | Yale University New Haven, CT | A | $114,679 | paid | 2021 BEE: BENVENISTE TANNENBAUM: BRAIN ENTRY & EXIT CONSORTIUM: GLYMPHATIC-LYMPHATIC COUPLING IN ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | Massachusetts Institute of Techonology Cambridge, MA | A | $100,000 | paid | (YR 2) BRAIN ENTRY & EXIT CONSORTIUM: HUMAN 3D NEUROVASCULAR INTERACTION AND MENINGEAL LYMPHATICS MODELS WITH APPLICATION TO ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | Amylyx Cambridge, MA | A | $78,234 | paid | PEGASUS CLINICAL STUDY OF AMX0035 IN ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | Massachusetts General Hospital Boston, MA | A | $58,090 | paid | HIGH-THROUGHPUT DRUG SCREENING FOR ALZHEIMER'S DISEASE USING 3D HUMAN | 202241309349304019 |
| 2021 | Stonybrook University Stoney Book, NY | A | $50,051 | paid | 3DDS CONSORTIUM: PROTEOMICS OF ALZHEIMER'S DISEASE 3D CULTURES | 202241309349304019 |
| 2021 | The Brain Donor Project Naples, FL | A | $35,050 | paid | TARGET RECRUITMENT OF UNDERREPRESENTED AMERICANS FOR BRAIN DONOR REGISTRATION | 202241309349304019 |
| 2021 | Houston Methodist Hospital Foundation Houston, TX | A | $25,000 | paid | SUPPLEMENT | 202241309349304019 |
| 2021 | Massachusetts General Hospital Boston, MA | A | $25,000 | paid | MODULATING CD33 FUNCTION AND NEUROINFLAMMATION AS A THERAPEUTIC APPROACH FOR AD | 202241309349304019 |
| 2021 | The Trustees of Boston University Boston, MA | A | $25,000 | paid | BLOCKING SYNAPTOTOXICITY IN ALZHEIMER'S 3D MODELS | 202241309349304019 |
| 2020 | Massachusetts General Hospital Boston, MA | A | $1,725,000 | paid | THE CUREALZ ALZHEIMER'S GENOME PROJECT | 202141319349300914 |
| 2020 | The Broad Institute Inc Cambridge, MA | A | $550,000 | paid | CIRCUITS: CONSORTIUM TO INFER REGULATORY CIRCUITS AND UNCOVER INNOVATIVE THERAPEUTIC STRATEGIES PRODUCTION GROUP | 202141319349300914 |
| 2020 | Massachusetts General Hospital Boston, MA | A | $450,000 | paid | CHARACTERIZING GUT MICROBIOME SYNERGY WITH EMPHASIS ON MYCOBIOME AND ITS IMPACT ON ALZHEIMER'S DISEASE (AD) PATHOLOGY IN AD MOUSE MODEL | 202141319349300914 |
| 2020 | Massachusetts General Hospital Boston, MA | A | $402,500 | paid | 3DDS CONSORTIUM: MODULATING CD33 FUNCTION AND NEUROINFLAMMATION AS A THERAPEUTIC APPROACH FOR ALZHEIMER'S DISEASE | 202141319349300914 |
| 2020 | Massachusetts General Hospital Boston, MA | A | $350,000 | paid | MICROBES AND ALZHEIMER'S DISEASE: METAGENOMICS ON SALIVA, CSF, BLOOD AND BRAIN | 202141319349300914 |
| 2020 | Massachusetts General Hospital Boston, MA | A | $345,000 | paid | NEUROPROTECTIVE EFFECTS OF THE EXERCISE HORMONE IRISIN IN ALZHEIMER'S DISEASE (YEAR 2) CHOI & WRANN | 202141319349300914 |
| 2020 | Boston Childrens Hospital Boston, MA | A | $300,000 | paid | NEUROIMFLAMMATION CONSORTIUM: UNDERSTANDING THE CONSEQUENCES OF NON-CODING AD RISK ALLELES ON MICROGLIA FUNCTION | 202141319349300914 |
| 2020 | Washington University St Louis St Louis, MO | A | $300,000 | paid | APOE CONSORTIUM: UNDERSTANDING THE EFFECT OF APOE ON TAU-MEDIATED NEURODEGENERATION (YEAR 3) | 202141319349300914 |
| 2020 | The University of California San Diego La Jolla, CA | A | $259,366 | paid | COMPREHENSIVE ANALYSES OF CHRONIC EFFICACY STUDIES WITH GSM 776890 FOR SUBMISSION OF THE PRE-IND BROCHURE TO THE FDA PRIOR TO PRE-IND MEETING AND IND FILING FOR THE SAD/MAD PHASE I SAFETY/TOXICITY AND ULTIMATELY FOR PHASE II AND PHASE III EFFICACY CLINICAL TRIALS TO SUPPORT THE NDA | 202141319349300914 |
| 2020 | The University of California Irvine Irvine, CA | A | $250,000 | paid | NEUROINFLAMMATION CONSORTIUM: EXAMINING THE ROLE OF HUMAN MICROGLIA IN THE TRANSITION BETWEEN PARENCHYMAL AND VASCULAR BETAAMYLOID PATHOLOGY | 202141319349300914 |
| 2020 | New York University School of Medicine New York, NY | A | $250,000 | paid | NEUROINFLAMMATION CONSORTIUM: INVESTIGATION OF AD RISK ALLELES IN ASTROCYTES FOCUS ON CHOLESTEROL TRANSPORT AND MICROGLIA INTERACTIONS (YEAR 2) | 202141319349300914 |
| 2020 | Mayo Clinic Jacksonville Jacksonville, FL | A | $250,000 | paid | APOE CONSORTIUM: COUNTERACTING PATHOGENIC EVENTS IN AD WITH PERIPHERAL OR CENTRAL APOE (YEAR 3) | 202141319349300914 |
| 2020 | The University of California San Diego La Jolla, CA | A | $250,000 | paid | NEUROINFLAMMATION CONSORTIUM: USING EPIGENETICS TO CHARACTERIZE THE REGULATION OF CELLULAR STATES IN MICROGLIA THAT CONTRIBUTE TO ALZHEIMER'S DISEASE PATHOLOGY | 202141319349300914 |
| 2020 | University of Southern California Los Angeles, CA | A | $250,000 | paid | MOLECULAR SIGNATURES OF APOE-MEDIATED BLOOD-BRAIN BARRIER DYSFUNCTION CAUSING NEURONAL AND SYNAPTIC DYSFUNCTION | 202141319349300914 |
| 2020 | The Rockefeller University New York, NY | A | $250,000 | paid | APOE CONSORTIUM: REGULATION BY APOE OF SELECTIVE NEURONAL VULNERABILITY TO ALZHEIMER'S DISEASE (YEAR 3) | 202141319349300914 |
| 2020 | Brigham and Women's Hospital Boston, MA | A | $250,000 | paid | THE ROLE OF APOE IN MICROGLIA REGULATIONS IN NEURODEGENERATION (YEAR 3) | 202141319349300914 |
| 2020 | Harvard College Boston, MA | A | $250,000 | paid | NEUROINFLAMMATION CONSORTIUM: ASSESSING THE LINKS BETWEEN THE MS4A RISK GENES, MICROGLIA, AND ALZHEIMER'S DISEASE | 202141319349300914 |
| 2020 | University of Texas Southwestern Medical Center Dallas, TX | A | $250,000 | paid | MECHANISMS OF TAU PROPAGATION ACROSS THE PLASMA MEMBRANE | 202141319349300914 |
| 2020 | Mgh Neurology Reasearch Boston, MA | A | $250,000 | paid | CREATION OF FIBROBLAST/IPS CELL BANK TO FACILITATE PERIPHERAL/BRAIN COMPARISONS, AND ALLOW MOLECULAR INVESTIGATIONS INTO MOLECULAR MECHANISMS UNDERLYING DIFFERENCES IN DISEASE AGGRESSIVENESS (YEAR 1) | 202141319349300914 |
| 2020 | Washington University St Louis St Louis, MO | A | $247,922 | paid | APOE CONSORTIUM: ASSESSING THE ADDED DIAGNOSTIC VALUE OF PERIPHERAL APOE PROTEIN LEVELS IN CURRENT BLOOD-BASED BIOMARKER ASSAYS FOR CNS AMYLOIDOSIS (YEAR 3) | 202141319349300914 |
| 2020 | University of Virginia Charlottesville, VA | A | $229,249 | paid | ADULT HUMAN INERONS: A NEXT GENERATION DRUG SCREENING PLATFORM FOR ALZHEIMER'S DISEASE | 202141319349300914 |
| 2020 | Duke University School of Medicine Durham, NC | A | $203,281 | paid | SEX DIFFERENCES IN ALZHEIMER'S DISEASE PROGRESSION: FRAMINGHAM HEART STUDY | 202141319349300914 |
| 2020 | Houston Methodist Hospital Foundation Houston, TX | A | $200,000 | paid | 3DDS CONSORTIUM: UNCOVERING THE MOLECULAR MECHANISMS OF SELECTED DRUG CANDIDATES DERIVED FROM SYSTEMATIC ALZHEIMER'S DRUG REPOSITIONING | 202141319349300914 |
| 2020 | The University of California San Diego La Jolla, CA | A | $172,500 | paid | THE NEDD4-1 AND PKCA CONNECTION IN ALZHEIMER'S DISEASE (YEAR 1) | 202141319349300914 |
| 2020 | Washington University St Louis St Louis, MO | A | $172,500 | paid | INVESTIGATING THE CONTRIBUTION OF ASTROCYTIC-DEPENDENT INFLAMMATION ON AMYLOID INDUCED TAU PATHOLOGY | 202141319349300914 |
| 2020 | University of North Carolina Chapel Hill Chapel Hill, NC | A | $172,500 | paid | SMALL MOLECULE ACTIVATORS OF PLC-Y2 AS NOVEL | 202141319349300914 |
| 2020 | Weill Medical College of Cornell University New York, NY | A | $172,500 | paid | GUT MICROBIOTA, ENDOTHELIAL DYSFUNCTION AND TAU-MEDIATED COGNITIVE IMPAIRMENT | 202141319349300914 |
| 2020 | Yale University New Haven, CT | A | $172,500 | paid | ROLE OF MICROGLIAL PROTEIN SPARC IN CONTROL OF INFLAMMASOME ACTIVATION (YEAR 2 OF 2) | 202141319349300914 |
| 2020 | Massachusetts General Hospital Boston, MA | A | $172,500 | paid | GENES TO THERAPIES (G2T) CENTRALIZED RESEARCH | 202141319349300914 |
| 2020 | Weill Medical College of Cornell University New York, NY | A | $172,500 | paid | VHTS FOR CD33 INHIBITORS | 202141319349300914 |
| 2020 | Beth Israel Deaconess Medical Center Boston, MA | A | $172,500 | paid | CIRCUITS: INTERGRATING FUNCTIONAL MAPS TO DISCOVER MICRO RNA'S IN AD | 202141319349300914 |
| 2020 | Harvard College Boston, MA | A | $172,500 | paid | ANALYTICAL AND STATISTICAL TOOLS FOR SEQUENCE ANALYSIS FOR ALZHEIMER'S DISEASE | 202141319349300914 |
| 2020 | Mayo Clinic Jacksonville Jacksonville, FL | A | $172,500 | paid | ABCA7 LOSS OF FUNCTION IN AGING AND ALZHEIMER'S DISEASE (YEAR 1) | 202141319349300914 |
| 2020 | Mayo Clinic Rochester, MN | A | $172,500 | paid | SENESCENT CELLS AND ALZHEIMER'S DISEASE (YEAR 2) | 202141319349300914 |
| 2020 | Wake Forest University Health Services Winstonsalem, NC | A | $172,500 | paid | INVESTIGATING THE ROLE OF TAU PROTEIN IN NEURONAL SENESCENCE INDUCTIONAND MAINTENANCE (YEAR 1) | 202141319349300914 |
| 2020 | Whitehead Institute for Biomedical Research Cambridge, MA | A | $172,500 | paid | CIRCUITS: IMPACT OF GENETIC, EPIGENETIC AND CELLULAR VARIANTS ON ALZHEIMER'S DISEASE PATHOLOGY | 202141319349300914 |
| 2020 | Stanford University Stanford, CA | A | $172,500 | paid | A TRANSCRIPTIONAL REJUVENATION SIGNATURE FOR ALZHEIMER'S DISEASE | 202141319349300914 |
| 2020 | The Trustees of Boston University Boston, MA | A | $172,500 | paid | 3DDS CONSORTIUM: PROTEOMICS OF ALZHEIMER'S DISEASE 3D CULTURES | 202141319349300914 |
| 2020 | Trustees of Tufts College Boston, MA | A | $172,500 | paid | IN VIVO CHARACTERIZATION OF A LOSS OF FUNCTION GGA3 RARE VARIANT ASSOCIATED WITH AD (YEAR 1) | 202141319349300914 |
| 2020 | Icahn School of Medicine at Mount Sinai New York, NY | A | $172,500 | paid | VGF-DERIVED PEPTIDE THERAPY FOR AD: STUDIES OF MOUSE AND HUMAN TLQP-21 AND ITS RECEPTOR, C3AR1 (YEAR 1) | 202141319349300914 |
| 2020 | University of Chicago Chicago, IL | A | $168,434 | paid | EFFECT OF GUT MICROBIOME DYSBIOSIS ON NEUROINFLAMMATION AND A-DEPOSITION: A LONGITUDINAL MICRO-PET STUDY IN ALZHEIMER'S TRANSGENIC MICE | 202141319349300914 |
| 2020 | The University of California San Diego La Jolla, CA | A | $143,750 | paid | PHARMACOLOGICALLY PROTECTING AND RESCUING SYNAPSES FROM BETA AMYLOID BY RAISING SYNAPTIC PSD-95 (YEAR 2) | 202141319349300914 |
| 2020 | The Salk Institute for Biological Studies La Jolla, CA | A | $115,000 | paid | CIRCUITS: IMPACT OF GENETIC, EPIGENETIC AND CELLULAR VARIANTS ON ALZHEIMER'S DISEASE PATHOLOGY | 202141319349300914 |
| 2020 | Albert Einstein College of Medicine Bronx, NY | A | $100,000 | paid | IMPROVING ALZHEIMERS DISEASE CLINICAL TRIALS DESIGN BY MACHINE LEARNING LABS | 202141319349300914 |
| 2020 | Amylyx Cambridge, MA | A | $100,000 | paid | UNDERSTANDING AND MIMICKING THE BIOLOGICAL EFFECTS OF THE PLCY2 P522R VARIANCE THAT PROTECT AGAINST AD | 202141319349300914 |
| 2020 | The University of California San Diego La Jolla, CA | A | $98,921 | paid | ABETA MEDIATED INHIBITION OF GAMMA-SECRETASE ACTIVITY INDUCES AD-RELEVANT CELLULAR PHENOTYPES(YEAR 2) | 202141319349300914 |
| 2020 | Washington University St Louis St Louis, MO | A | $21,984 | paid | CHARACTERIZATION OF ALZHEIMER'S DISEASE MOLECULAR BIOMARKER PROFILES THROUGHOUT THE PATHOLOGICAL CONTINUUM (YEAR 1) | 202141319349300914 |
| 2019 | Massachusetts General Hospital Boston, MA | A | $1,475,000 | paid | ALZHEIMER'S GENOME PROJECT | 202041559349301614 |
| 2019 | The Broad Institute Inc Cambridge, MA | A | $750,000 | paid | PRODUCTION CENTER FOR REFERENCE AND VARIATION GENE-REGULARTORY MAPS | 202041559349301614 |
| 2019 | Amylyx Cambridge, MA | A | $750,000 | paid | PEGASUS CLINICAL STUDY OF AMX0035 IN ALZHEIMERS DISEASE; DRUG DEVELOPEMENT | 202041559349301614 |
| 2019 | Massachusetts General Hospital Boston, MA | A | $350,000 | paid | TAU AND B-AMYLOID ARE INNATE IMMUNE ANTIMICROBIAL PEPTIDES IN THE BRAIN | 202041559349301614 |
| 2019 | Washington University St Louis St Louis, MO | A | $345,000 | paid | ROLE IN MODULATING AB AND TAU-RELATED PATHOLOGIES AND NEURODENERATION | 202041559349301614 |
| 2019 | Brigham and Women's Hospital Boston, MA | A | $345,000 | paid | THE ROLE OF MFND-NEAURODEGENERATIVE CLEC7A+MICROGLIA IN AN AD MOUSE MODEL; TARGETING THE MICROBIOME AND MICROGLIA IN AD | 202041559349301614 |
| 2019 | Massachusetts General Hospital Boston, MA | A | $345,000 | paid | INHIBITING CD33 FUNCTION AND MODULATING MICROGLIAL ACTIVATION STATE FOR ALZHEIMER'S DISEASE THERAPY | 202041559349301614 |
| 2019 | University of Southern California Los Angeles, CA | A | $345,000 | paid | MOLECULAR SIGNATURES OF APOE-MEDIATED BLOOD BRAIN BARRIER DYSFUNCTION CAUSING NEURONAL AND SYNAPTIC DYSFUNCATION | 202041559349301614 |
| 2019 | Washington University St Louis St Louis, MO | A | $345,000 | paid | BERG BRAIN ENTRY & EXIT CONSORTIUM: CROSSTALK OF DNS BARRIERS AND CLEARANCE ROUTES IN HOMEOSTASIS AND AD | 202041559349301614 |
| 2019 | Massachusetts General Hospital Boston, MA | A | $300,000 | paid | UNDERSTANDING HUMAN BRAIN RESILIENCE TO ALZHEIMER'S PATHOLOGY | 202041559349301614 |
| 2019 | Boston Childrens Hospital Boston, MA | A | $298,115 | paid | MICROGLIAL HETEROGENEITY AND TRANSCIPTIONAL STATE CHANGES IN ALZHEIMER'S DISEASE. | 202041559349301614 |
| 2019 | The Regents of the University of California Oakland, CA | A | $287,500 | paid | ALZHEIMERS DISEASE-ASSOCIATED MUTATIONS IN PROTEIN KINASE C | 202041559349301614 |
| 2019 | Massachusetts General Hospital Boston, MA | A | $287,500 | paid | HIGH THROUGH PUT DRUG SCREENING FOR AD USING 3D HUMAN NEURAL CULTURE SYSTEMS | 202041559349301614 |
| 2019 | Houston Methodist Hospital Foundation Houston, TX | A | $287,500 | paid | UNCOVERING THE MOLECULAR MECHANISM OF SELECTED DRUG CANDIDATES DERIVED FROM SYSTEMATIC ALZHEIMER'S DRUG REPOSITIONING | 202041559349301614 |
| 2019 | Massachusetts General Hospital Boston, MA | A | $250,000 | paid | GUT MICROBIOME MEDIATED SHIFTS IN B-AMYLOID DEPOSITION IN A HUMANIZED AD MOUSE MODEL | 202041559349301614 |
| 2019 | Northwestern University Evanston, IL | A | $250,000 | paid | MOLECULAR AND CELLULAR MECHANISMS OF ACE1 R1279Q IN AD | 202041559349301614 |
| 2019 | New York University School of Medicine New York, NY | A | $250,000 | paid | NEUROTOXIC REACTIVE ASTROCYES IN ALZHEIMER'S DISEASE | 202041559349301614 |
| 2019 | The Regents of the University of California Oakland, CA | A | $250,000 | paid | INTERPRETATION OF NON-CODING RISK ALLELES OF AD | 202041559349301614 |
| 2019 | Massachusetts General Hospital Boston, MA | A | $250,000 | paid | NEUROIMMUNE MOLECULAR IMAGING: REDEFINING THE LANDSCAPE OF OPPORTUNITIES IN AD | 202041559349301614 |
| 2019 | Harvard College Boston, MA | A | $250,000 | paid | ASSESSING THE LINKS BETWEEN THE MS4A RISK GENESE, MICROGLIA, AND ALZHEIMER'S DISEASE | 202041559349301614 |
| 2019 | The University of California San Diego La Jolla, CA | A | $237,500 | paid | IDENTIYING THE BLOOD BRAIN BARRIER CHANGES DURING AD | 202041559349301614 |
| 2019 | The University of California San Diego La Jolla, CA | A | $230,000 | paid | THE EFFECT OF CHRONIC GAMMA-SECRETED MODULATION ON THE PREVENTION OF TBI-PROVOKED AND AD-RELEVANT BIOCHEMICAL PATHOLOGICAL AND BEHAVIORAL ALTERATIONS | 202041559349301614 |
| 2019 | University of Chicago Chicago, IL | A | $200,000 | paid | IN VITRO AND IN VIVO ANALYSIS OF AN APP VARIANT | 202041559349301614 |
| 2019 | Carnegie Mellon University Pittsburgh, PA | A | $199,013 | paid | CIRCUITS: INTERPRETING ALZHEIMER'S DISEASE-ASSOCIATED GENETIC VARIATION AT ENHANGER REGION | 202041559349301614 |
| 2019 | Weill Medical College of Cornell University New York, NY | A | $173,486 | paid | AD RISK IS HIGHER IN WOMEN: IDENTIFICATION OF FEMALE SPECIFIC BRAIN BIOENERGETIC TARGETS | 202041559349301614 |
| 2019 | University of Southern California Los Angeles, CA | A | $172,565 | paid | THE ROLE OF TREM2, APOE AND SEX | 202041559349301614 |
| 2019 | Palo Alto Veterans Institute for Research Palo Alto, CA | A | $172,500 | paid | REJUVENATION OF MICROGLIA IN BRAIN AGING AND NEURODEGENERATION | 202041559349301614 |
| 2019 | Massachusetts General Hospital Boston, MA | A | $172,500 | paid | GENES TO THERAPIES CENTRALIZED RESEARCH CORE | 202041559349301614 |
| 2019 | Washington University St Louis St Louis, MO | A | $172,500 | paid | MODELING AD IN SPECIFIC SUBTYPES OF HUMAN NEURONS THROUGH DIRECT NEURONAL REPROGRAMMING OF PATIENT FIBROBLASTS. | 202041559349301614 |
| 2019 | The Trustees of Boston University Boston, MA | A | $172,500 | paid | EVALUATION OF THE EFFECT OF CELL TYPE- SPECIFIC DELETION OF ESCRT GENES ON THE SPREAD OF TAU PATHOLOGY | 202041559349301614 |
| 2019 | Sanford Burnham Prebys Medical Discovery Institute La Jolla, CA | A | $172,500 | paid | MECHANISMS FOR AD-ASSOCIATED DORLA MUTATIONS IN MICROGLIA AND NEURONS IN AD PATHOGENESIS | 202041559349301614 |
| 2019 | Mayo Clinic Jacksonville Jacksonville, FL | A | $172,500 | paid | 2019 FITZPATRICK PETRUCELLI: PT-BASE STRUCTURAL AND FUNCTIONAL BIOLOGY OF TAUOPATHIES. | 202041559349301614 |
| 2019 | Harvard College Boston, MA | A | $172,500 | paid | ACTIVATION OF THE 26S PROTEASOME FOR THE TREATMENT OF ALZHEIMER'S DISEASE | 202041559349301614 |
| 2019 | Whitehead Institute for Biomedical Research Cambridge, MA | A | $172,500 | paid | IMPACT OF GENETIC, EPIGENETIC AND CELLULAR VARIANTS ON AD PATHOLOGY | 202041559349301614 |
| 2019 | Massachusetts General Hospital Boston, MA | A | $172,500 | paid | IMAGING MICROGLIAL HOMEOSTASIS AND DISRUPTION P2RY12 RADIOTRACER DEVELOPMENT | 202041559349301614 |
| 2019 | University of Connecticut Health Center Farmington, CT | A | $172,500 | paid | PHYSIOLOGICAL METHOD FOR EARLY DETECTION OF SYNAPTIC VULNERABILITY IN AD MODEL ANIMALS | 202041559349301614 |
| 2019 | University of Texas Southwestern Medical Center Dallas, TX | A | $172,500 | paid | GENETIC TARGETS TO BLOCK TAU PROPAGATION: TEST KNOCKDOWN OF HSPG GENES IN VIVO | 202041559349301614 |
| 2019 | Weill Medical College of Cornell University New York, NY | A | $172,500 | paid | DIETARY SALT TAU PHOSPHRYLATION AND COGNITIVE IMPAIRMENT | 202041559349301614 |
| 2019 | Beth Israel Deaconess Medical Center Boston, MA | A | $172,500 | paid | UTILIZING FUNCTIONAL MAPS TO DISCOVER MICRO RNA'S IN AD | 202041559349301614 |
| 2019 | The Trustees of Boston University Boston, MA | A | $172,500 | paid | AD PHARMACOMICS IN 3D | 202041559349301614 |
| 2019 | The Regents of the University of California Oakland, CA | A | $172,500 | paid | HUMAN-SPECIFIC EVOLUTION OF CD33: EVOLUTIONARY RELATIONSHIP TO ANCIENT HOST-PATHOGEN INTERACTIONS AND CURRENT IMPLICATION FOR ALZHEIMER'S DISEASE | 202041559349301614 |
| 2019 | Mayo Clinic Rochester, MN | A | $172,500 | paid | THE ROLE OF CLUSTERIN IN TAU PATHOLOGY | 202041559349301614 |
| 2019 | The Rockefeller University New York, NY | A | $172,500 | paid | DISCOVERY OF CHEMICAL COMPOUNDS THAT INDUCE DEGRADATION OF APP-B-CTF IN CELLS | 202041559349301614 |
| 2019 | Washington University St Louis St Louis, MO | A | $172,500 | paid | HARNESSING BIG DATA TO UNDERSTAND AD RISK | 202041559349301614 |
| 2019 | Yale University New Haven, CT | A | $172,500 | paid | ROLE OF MICROGLIAL PROTEIN SPARC IN CONTROL OF INFLAMMASOME ACTIVATION | 202041559349301614 |
| 2019 | Washington University St Louis St Louis, MO | A | $172,497 | paid | THE CIRCADIAN CLOCK MODULATES NEURODENERATION IN AD VIA REVE-ERB | 202041559349301614 |
| 2019 | Massachusetts General Hospital Boston, MA | A | $172,443 | paid | DIRECT MIGRATION OF MYELOID CELLS FROM THE SKULL MARROW TO THE BRAIN THROUGH ANATOMICAL CHANNELS ADDING FUEL TO THE FILE IN AD | 202041559349301614 |
| 2019 | Massachusetts General Hospital Boston, MA | A | $171,914 | paid | INTERLEUKIN-3 IN AD | 202041559349301614 |
| 2019 | Harvard College Boston, MA | A | $171,523 | paid | ANALYTICAL AND STATISTICAL TOOLS FOR SEQUENCE ANALYSIS FOR ALZHEIMER'S DISEASE | 202041559349301614 |
| 2019 | Washington University St Louis St Louis, MO | A | $154,701 | paid | CENTRAL CLOCK INFLUENCE ON ALZHEIMER'S DISEASE PATHOGENESIS | 202041559349301614 |
| 2019 | The Rockefeller University New York, NY | A | $150,000 | paid | STIMULATING PROTEASOME ACTIVITY FOR THE TREATMENT OF AD | 202041559349301614 |
| 2019 | Memorial Sloan Kettering Cancer Center New York, NY | A | $150,000 | paid | BIOCHEMICAL MAPPTING OF THE GSM BINDING SITE OF THE NOVEL PYRIDAZINE-DERIVED SMALL MOLECULE Y-SECRETASE MODULARS | 202041559349301614 |
| 2019 | Washington University St Louis St Louis, MO | A | $150,000 | paid | STABLE ISOTOPE LABELING & QUANTITATIVE MASS SPECTOMETRY IMAGING OF AD PATHOLOGY IN HUMAN BRAIN | 202041559349301614 |
| 2019 | Washington University St Louis St Louis, MO | A | $150,000 | paid | TARGETING REACTIVE ASTOCYTES FOR THERAPEUTIC INTERVENTION OF AD | 202041559349301614 |
| 2019 | The Regents of the University of California Oakland, CA | A | $150,000 | paid | BIOCHEMICAL MAPPING OF THE GSM BINDING SITE OF THE NOVEL PYRIDAZINE-DERIVED SMALL MOLECULE Y-SECRETASE MODULATORS | 202041559349301614 |
| 2019 | Icahn School of Medicine at Mount Sinai New York, NY | A | $150,000 | paid | VGF, A NOVEL THERAPEUTIC EFFECTOR OF AD PATHOGENESIS AND PROGRESSION | 202041559349301614 |
| 2019 | The Regents of the University of California Oakland, CA | A | $150,000 | paid | TREATING WITH GAMMA-SECRETASE MODULATORS TO PREVENT NEAURDENERATION IN MOUSE MODELS OF DOWN SYNDROME AND AD | 202041559349301614 |
| 2019 | Weill Medical College of Cornell University New York, NY | A | $150,000 | paid | REGULATION OF MIRCOGLIAL LYSOSOME ACIDIFICATION | 202041559349301614 |
| 2019 | Massachusetts General Hospital Boston, MA | A | $115,000 | paid | HUMAN 3D NEURO-VASCULAR INTERACTION AND MENINGEAL LYMPHATIC MODELS WITH APPLICATION TO AD | 202041559349301614 |
| 2019 | Northwestern University Evanston, IL | A | $115,000 | paid | THE ROLE OF IMPAIRED SYNAPTIC VESICLE MACHINERY PROTEOSTATSIS IN ALZHEIMER'S DISEASE PATHOGENESIS | 202041559349301614 |
| 2019 | The Salk Institute for Biological Studies La Jolla, CA | A | $115,000 | paid | IMPACT OF GENETIC, EPIGENETIC AND CELLULAR VARIANTS ON AD PATHOLOGY. | 202041559349301614 |
| 2019 | Massachusetts General Hospital Boston, MA | A | $108,726 | paid | AN INNOVATIVE STUDY OF THE PUPIL LIGHT REFLEX IN AD | 202041559349301614 |
| 2019 | Washington University St Louis St Louis, MO | A | $103,016 | paid | CHARACTERIZATION OF AD MOLECULAR BIOMARKER PROFILES THROUGHOUT THE PATHOBIOLOICAL CONTINUUM | 202041559349301614 |
| 2019 | Massachusetts Institute of Technology Cambridge, MA | A | $100,000 | paid | HUMAN 3D NEURO-VASCULAR INTERACTION AND MENINGEAL LYMPHATICS MODELS WITH APPLICATION TO AD | 202041559349301614 |
| 2019 | Duke University School of Medicine Durham, NC | A | $91,687 | paid | A NOVEL APOE MIMETIC THERAPEUTIC PEPTIDE CN-105 ATTENUATES AD PATHOLOGY AND IMPROVES FUNCATIONAL OUTCOMES IN A MURINE MODEL OF AD | 202041559349301614 |
| 2019 | Columbia University New York, NY | A | $83,375 | paid | 2019 FITZPATRICK PETRUCELLI: PT BASED STRUCTURAL AND FUNCTIONAL BIOLOGY OF TAUOPATHIES | 202041559349301614 |
| 2019 | University of Rhode Island Kingston, RI | A | $56,404 | paid | CEREBROVASCULAR DYSFUNCTION IN AD: TARGETING THE MECHANISMS OF VASCULAR ACTIVATION | 202041559349301614 |
| 2018 | Massachusetts General Hospital Boston, MA | A | $1,725,000 | paid | ALZHEIMER'S GENOME PROJECT | 201901159349300235 |
| 2018 | The Rockefeller University New York, NY | A | $517,500 | paid | DISCOVERY OF CHEMICAL COMPOUNDS THAT INDUCE DEGRADATION OF APP-B-CTF IN CELLS | 201901159349300235 |
| 2018 | Massachusetts Institute of Technology Cambridge, MA | A | $460,000 | paid | FUNCTIONAL ANALYSIS OF AD RISK GENES USING HUMAN INDUCED PLURIPOTENT STEM CELLS | 201901159349300235 |
| 2018 | The University of California San Diego La Jolla, CA | U | $373,750 | paid | PHARMACOLOGICALLY PROTECTING AND RESCUING SYNAPSES FROM BETA AMYLOID BY RAISING SYNAPTIC PSD-95 HEAD | 201901159349300235 |
| 2018 | Massachusetts General Hospital Boston, MA | A | $345,000 | paid | HIGH THROUGH PUT DRUG SCREENING FOR AD USING 3D HUMAN NEURAL CULTURE SYSTEMS | 201901159349300235 |
| 2018 | Massachusetts General Hospital Boston, MA | A | $345,000 | paid | NEUROPROTECTIVE EFFECTS OF THE EXERCISE HORMONE IRISIN IN AD | 201901159349300235 |
| 2018 | University of Southern California Los Angeles, CA | A | $345,000 | paid | THE ROLE OF PICALM MUTATIONS IN AD | 201901159349300235 |
| 2018 | Washington University St Louis St Louis, MO | U | $300,000 | paid | UNDERSTANDING THE EFFECT OF APOE ON TAU-MEDIATED NEURODENERATION | 201901159349300235 |
| 2018 | Massachusetts General Hospital Boston, MA | A | $300,000 | paid | UNDERSTANDING HUMAN BRAIN RESILIENCE TO ALZHEIMER'S PATHOLOGY | 201901159349300235 |
| 2018 | University of Southern California Los Angeles, CA | A | $300,000 | paid | PICALM GENE THERAPY AND DRUG SCREENING FOR AMYLOID BETA CLEARANCE | 201901159349300235 |
| 2018 | Boston Childrens Hospital Boston, MA | A | $299,924 | paid | MICROGLIAL HETEROGENEITY AND TRANSCRIPTIONAL STATE CHANGES IN ALZHEIMER'S DISEASE | 201901159349300235 |
| 2018 | The University of California San Diego La Jolla, CA | U | $287,500 | paid | AD RELATED MUTATIONS IN PROTEIN KINASE C | 201901159349300235 |
| 2018 | Massachusetts General Hospital Boston, MA | A | $287,500 | paid | ROLE OF ATXN1 IN REGULATING BACE1 ACTIVITY | 201901159349300235 |
| 2018 | Houston Methodist Hospital Foundation Houston, TX | A | $287,500 | paid | UNCOVERING THE MOLECULAR MECHANISM OF SELECTED DRUG CANDIDATES DERIVED FROM SYSTEMATIC ALZHEIMER'S DRUG REPOSITIONING | 201901159349300235 |
| 2018 | The Regents of the University of California Oakland, CA | A | $250,000 | paid | INTERPRETATION OF NON-CODING RISK ALLELES OF AD | 201901159349300235 |
| 2018 | Brigham and Women's Hospital Boston, MA | A | $250,000 | paid | THE ROLE OF APOE IN MICROGLIA REGULATION IN NEURODEGENERATION | 201901159349300235 |
| 2018 | Mayo Clinic Jacksonville Jacksonville, FL | A | $250,000 | paid | APOE: BU YEAR 2 | 201901159349300235 |
| 2018 | Washington University St Louis St Louis, MO | U | $250,000 | paid | APOE PROTEOFORMS IN HUMAN CNS AND VALIDATION OF TRANSLATIONAL APOE PHARMACODYNAMIC MARKERS | 201901159349300235 |
| 2018 | The Rockefeller University New York, NY | A | $250,000 | paid | IMPACT OF APOE AND SEX ON VULNERABLE NEURON-SPECIFIC FUNCTIONAL NETWORKS | 201901159349300235 |
| 2018 | New York University School of Medicine New York, NY | C | $250,000 | paid | NEUROTOXIC REACTIVE ASTROCYES IN ALZHEIMER'S DISEASE | 201901159349300235 |
| 2018 | Harvard College Boston, MA | A | $250,000 | paid | ANALYTICAL AND STATISTICAL TOOLS FOR SEQUENCE ANALYSIS FOR ALZHEIMER'S DISEASE | 201901159349300235 |
| 2018 | Harvard College Boston, MA | A | $250,000 | paid | ASSESSING THE LINKS BETWEEN THE MS4A RISK GENESE, MICROGLIA, AND ALZHEIMER'S DISEASE | 201901159349300235 |
| 2018 | University of Michigan Ann Arbor, MI | U | $241,738 | paid | 2018 PAULSON GIORDANI HAMPSTEAD | 201901159349300235 |
| 2018 | University of Virginia Charlottesville, VA | U | $230,000 | paid | MENINGEAL LYMPHATIC FUNCTION AND ANTIBODY THERAPY IN AD | 201901159349300235 |
| 2018 | University of Virginia Charlottesville, VA | U | $230,000 | paid | CELL CYCLE RE-ENTRY IN 3D HUMAN NEURON CULTURES | 201901159349300235 |
| 2018 | Beth Israel Deaconess Medical Center Boston, MA | A | $209,725 | paid | UTILIZING FUNCTIONAL MAPS TO PRIORITIZE THERAPEUTIC TARGETS IN AD | 201901159349300235 |
| 2018 | University of North Carolina at Charlotte Charlotte, NC | B | $200,000 | paid | STUDY OF REACTIVE ASTROCYTES DERIVED OXIDATIVE STRESS AND MICROGLIAL NEURODEGENERATIVE INFLAMMATION IN AD | 201901159349300235 |
| 2018 | Carnegie Mellon University Pittsburgh, PA | A | $198,021 | paid | CIRCUITS: INTERPRETING ALZHEIMER'S DISEASE-ASSOCIATED GENETIC VARIATION AT ENHANGER REGION | 201901159349300235 |
| 2018 | Massachusetts General Hospital Boston, MA | A | $193,890 | paid | GENES TO THERAPIES CENTRALIZED RESEARCH CORE | 201901159349300235 |
| 2018 | Whitehead Institute for Biomedical Research Cambridge, MA | A | $178,250 | paid | WHOLE GENOME CHARACTERIZATION OF DNA METHYLATION CHANGES IN THE AGED AND AD | 201901159349300235 |
| 2018 | University of Connecticut Health Center Farmington, CT | U | $172,500 | paid | PHYSIOLOGICAL METHOD FOR EARLY DETECTION OF SYNAPTIC VULNERABILITY IN AD MODEL ANIMALS | 201901159349300235 |
| 2018 | Northwestern University Evanston, IL | A | $172,500 | paid | THE ROLE OF IMPAIRED SYNAPTIC VESICLE MACHINERY PROTEOSTATSIS IN ALZHEIMER'S DISEASE PATHOGENESIS | 201901159349300235 |
| 2018 | Massachusetts General Hospital Boston, MA | A | $172,500 | paid | IMAGING MICROGLIAL HOMEOSTASIS AND DISRUPTION P2RY12 RADIOTRACER DEVELOPMENT | 201901159349300235 |
| 2018 | The University of California San Diego La Jolla, CA | U | $172,500 | paid | IDENTIYING THE BLOOD BRAIN BARRIER CHANGES DURING AD | 201901159349300235 |
| 2018 | Massachusetts General Hospital Boston, MA | A | $172,500 | paid | THE IMPACT OF AD-ASSOCIATED GENETIC VARIANTS IN 3D HUMAN MIXED NEURALGLIAL MODELS OF AD | 201901159349300235 |
| 2018 | Weill Medical College of Cornell University New York, NY | U | $172,500 | paid | DIETARY SALT TAU PHOSPHRYLATION AND COGNITIVE IMPAIRMENT | 201901159349300235 |
| 2018 | Palo Alto Veterans Institute for Research Palo Alto, CA | A | $172,500 | paid | REJUVENATION OF MICROGLIA IN BRAIN AGING AND NEURODEGENERATION | 201901159349300235 |
| 2018 | The Trustees of Boston University Boston, MA | A | $172,500 | paid | AD PHARMACOMICS IN 3D | 201901159349300235 |
| 2018 | The Regents of the University of California Oakland, CA | A | $172,500 | paid | HUMAN-SPECIFIC EVOLUTION OF CD33: EVOLUTIONARY RELATIONSHIP TO ANCIENT HOST-PATHOGEN INTERACTIONS AND CURRENT IMPLICATION FOR ALZHEIMER'S DISEASE | 201901159349300235 |
| 2018 | Yale University New Haven, CT | A | $172,500 | paid | ROLE OF MICROGLIAL PROTEIN SPARC IN CONTROL OF INFLAMMASOME ACTIVATION | 201901159349300235 |
| 2018 | The Rockefeller University New York, NY | A | $172,500 | paid | YEAR 1: THE DEVELOPMENT OF DNA-ENCODED LIBRARIES TO DISCOVER THERAPEUTICALLY VALUABLE LOW MOLECULAR WEIGHT COMPOUNDS FOR AD | 201901159349300235 |
| 2018 | Massachusetts General Hospital Boston, MA | A | $172,500 | paid | INHIBITING CD33 FUNCTION AND MODULATING MICROGLIAL ACTIVATION STATE FOR ALZHEIMER'S DISEASE THERAPY | 201901159349300235 |
| 2018 | Massachusetts General Hospital Boston, MA | A | $172,500 | paid | THE ROLE OF NEUREXINS IN ALZHEIMER'S DISEASE | 201901159349300235 |
| 2018 | The Trustees of Boston University Boston, MA | A | $172,500 | paid | EVALUATION OF THE EFFECT OF CELL TYPE- SPECIFIC DELETION OF ESCRT GENES ON THE SPREAD OF TAU PATHOLOGY | 201901159349300235 |
| 2018 | Washington University St Louis St Louis, MO | U | $172,500 | paid | CENTRAL CLOCK INFLUENCE ON ALZHEIMER'S DISEASE PATHOGENESIS | 201901159349300235 |
| 2018 | Mayo Clinic Rochester, MN | A | $172,500 | paid | SENESCENT CELLS AND ALZHEIMER'S DISEASE | 201901159349300235 |
| 2018 | Washington University St Louis St Louis, MO | U | $172,500 | paid | MODELING AD IN SPECIFIC SUBTYPES OF HUMAN NEURONS THROUGH THE DIRECT NEURONAL REPROGRAMMING | 201901159349300235 |
| 2018 | Yale University New Haven, CT | A | $172,500 | paid | THE NEUROPROTECTIVE GLIAL BARRIER: A MULTICELLULAR REACTION WITH THERAPEUTIC POTENTIAL IN AD | 201901159349300235 |
| 2018 | University of Texas Southwestern Medical Center Dallas, TX | A | $172,500 | paid | GENETIC TARGETS TO BLOCK TAU PROPAGATION: TEST KNOCKDOWN OF HSPG GENES IN VIVO | 201901159349300235 |
| 2018 | University of Southern California Los Angeles, CA | A | $172,500 | paid | TARGETING BENEFICIAL INNATE IMMUNITY IN AD BY IRAK-M DELETION | 201901159349300235 |
| 2018 | Harvard College Boston, MA | A | $172,500 | paid | ACTIVATION OF THE 26S PROTEASOME FOR THE TREATMENT OF ALZHEIMER'S DISEASE | 201901159349300235 |
| 2018 | Washington University St Louis St Louis, MO | U | $172,137 | paid | THE CIRCADIAN CLOCK MODULATES NEURODENERATION IN AD VIA REVE-ERB | 201901159349300235 |
| 2018 | Massachusetts General Hospital Boston, MA | A | $171,932 | paid | INTERLEUKIN-3 IN AD | 201901159349300235 |
| 2018 | Massachusetts General Hospital Boston, MA | A | $170,907 | paid | EFFECTS OF CEREBROVASCULAR INSUFFICIENCY AND EXERCISE ON THE ALZHEIMER'S BRAIN | 201901159349300235 |
| 2018 | Weill Medical College of Cornell University New York, NY | U | $170,861 | paid | AD RISK IS HIGHER IN WOMEN: IDENTIFICATION OF FEMALE SPECIFIC BRAIN BIOENERGETIC TARGETS | 201901159349300235 |
| 2018 | The Trustees of Tufts College Medford, MA | C | $150,000 | paid | FUNCTIONAL CHARACTERIZATION OF GGA3 MUTATIONS ASSOCIATED WITH AD | 201901159349300235 |
| 2018 | The Rockefeller University New York, NY | A | $150,000 | paid | STRICKLAND NORRIS YEAR 2: THE ROLE OF THE CONTACT SYSTEM IN AD | 201901159349300235 |
| 2018 | Columbia University New York, NY | A | $150,000 | paid | NOVEL CHEMICAL MODULATION FOR BRACE 1-MEDIATED CLEAVAGE OF B-AMYLOID PRECURSOR PROTEIN | 201901159349300235 |
| 2018 | The Salk Institute for Biological Studies La Jolla, CA | A | $150,000 | paid | MICROGLIAL TAM RECEPTORS AS MODULATORS OF AD | 201901159349300235 |
| 2018 | Boston Childrens Hospital Boston, MA | A | $149,999 | paid | TEMPORAL ANALYSIS OF INFECTION IN ALZHEIMER'S DISEASE MODELS | 201901159349300235 |
| 2018 | Massachusetts General Hospital Boston, MA | A | $148,732 | paid | CIRCUITS: IPS CELLS AND THE HUMAN BRAINS | 201901159349300235 |
| 2018 | Massachusetts General Hospital Boston, MA | A | $143,750 | paid | INDENTIFYING BLOOD-BRAIN BARRIER ENHANCERS AND ROLE OF NEUTROPHILS IN A 3D BBB VASCULARIZED MODEL OF ALZHEIMER'S DISEASE | 201901159349300235 |
| 2018 | Massachusetts Institute of Technology Cambridge, MA | A | $125,000 | paid | IDENTIFYING BLOOD-BRAIN BARRIER ENHANCERS AND ROLE OF NEUTROPHILS IN A BB VASCULARIZED MODEL OF ALZHEIMER'S DISEASE | 201901159349300235 |
| 2018 | The Salk Institute for Biological Studies La Jolla, CA | A | $109,250 | paid | WHOLE GENOME CHARACTERIZATION OF DNA METHYLATION CHANGES IN THE AGED AND AD | 201901159349300235 |
| 2018 | The Regents of the University of California Oakland, CA | A | $100,479 | paid | ABETA MEDIATED INHIBITION OF GAMMA-SECRETASE ACTIVITY INDUCES AD-RELEVANT CELLULAR PHENOTYPES MOBLEY | 201901159349300235 |
| 2018 | Massachusetts General Hospital Boston, MA | A | $100,000 | paid | NEUROIMMUNE MOLECULAR IMAGING: REDEFINING THE LANDSCAPE OF OPPORTUNITIES IN AD | 201901159349300235 |
| 2018 | Washington University St Louis St Louis, MO | U | $79,594 | paid | SCIENTIFIC DIRECTIONS FOR THE EXPLORATIONS OF RACIAL DISPARITIES IN AD | 201901159349300235 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.
Source filings
Every figure above is traceable to one of these IRS e-file returns by its OBJECT_ID.
| Form | Tax year | Period end | Filed | Schema | IRS OBJECT_ID |
|---|---|---|---|---|---|
| 990 | 2025 | 2025-12-31 | not stated | 2025v4.1 | 202641319349301469 |
| 990 | 2024 | 2024-12-31 | not stated | 2024v5.1 | 202531289349302248 |
| 990 | 2023 | 2023-12-31 | not stated | 2023v5.0 | 202421229349300027 |
| 990 | 2022 | 2022-12-31 | not stated | 2022v5.0 | 202331259349301933 |
| 990 | 2021 | 2021-12-31 | not stated | 2021v4.2 | 202241309349304019 |
| 990 | 2020 | 2020-12-31 | not stated | 2020v4.1 | 202141319349300914 |
| 990 | 2019 | 2019-12-31 | not stated | 2019v5.1 | 202041559349301614 |
| 990 | 2018 | 2018-12-31 | not stated | 2018v3.1 | 201901159349300235 |
Derived from IRS Form 990 e-file XML; recipient identities from the IRS Exempt Organizations Business Master File. Dataset version 2026.09.0, built 2026-09-03. The same rows as Parquet: manifest; as JSON: /api/funders/522396428.json.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.